Psychotropic agents and their use for treatment of psychiatric and neurological conditions and conditions
Methyl ketone, 2C-B, and MBDB offer rapid and effective treatment for neuropsychiatric disorders by minimizing side effects and interactions, expanding treatment accessibility for conditions like depression and PTSD.
Patent Information
- Application Number
- CN202380031652.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-01-04
- Filing Date
- 2023-02-02
- Publication Date
- 2024-12-06
AI Technical Summary
Current psychoactive drugs like MDMA and psilocybin have limited efficacy and are contraindicated for many patients due to safety concerns, drug interactions, and require intensive monitoring, limiting their accessibility and effectiveness for treating neuropsychiatric disorders such as depression and PTSD.
Administering therapeutically effective amounts of methyl ketone, 2C-B, or MBDB, either alone or in combination with other psychoactive agents, to treat neuropsychiatric disorders, with dosing schedules ranging from single doses to extended release formulations to minimize side effects and improve accessibility.
These compounds provide rapid antidepressant and anxiolytic effects with fewer side effects, better safety profiles, and reduced drug interactions, making them suitable for a wider range of patients, including those refractory to standard treatments.
Smart Images

Figure CN119095593A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to psychotropic drugs including methyl ketones, 2C-B, MBDB, their respective metabolites, isomers, enantiomers, polymorphs and analogs (2C series and cathinone); their preparation, formulation, intermediates, routes of administration, dosages and schedules for medical use in psychiatric and neurological conditions and disorders. Background Art
[0002] Classical hallucinogens are a class of mixed serotonin-activating, norepinephrine-activating and dopamine-activating modulatory compounds, generally of ethnobotanical origin. These heterogeneous agents are psychoactive and can alter perception, mood and many other cognitive and physiological processes. Anthropological studies indicate that they had ritual uses in societies ranging from the ancient Near East, the Mediterranean basin and Mesoamerica. After the discovery and synthesis of the tryptamine analog lysergic acid-N,N-diethylamide (LSD) by Albert Hofmann in 1943, decades of promising clinical development and therapeutic exploration followed. However, the entire class of compounds is restricted by the mainstream scientific community, for example in the United States, by the Controlled Substances Act of 1970 and characterized as "not for medical use".
[0003] The incidence of neuropsychiatric disorders such as treatment-resistant depression, fibromyalgia, and post-traumatic stress disorder (PTSD) is growing, and new treatments that meaningfully impact patients’ lives have been lacking. The dissociative anesthetic ketamine, or its enantiomer esketamine, was first approved in 2019 as Spravato for major depressive disorder (MDD) and / or suicidality. As of May 2021, there are three FDA breakthrough therapy designations for psychedelic drugs: 3,4-methylenedioxymethamphetamine (MDMA) for PTSD and psilocybin for both treatment-resistant depression (TRD) and MDD. There is growing recognition that current pharmacological interventions are limited in effectiveness, and that new psychoactive drugs are needed without provider-intensive safety and monitoring issues or contraindications for patients receiving existing medications, such as selective serotonin reuptake inhibitors (SSRIs) and other drug classes.
[0004] A Phase 3 trial investigating MDMA (3,4-methylenedioxy-N-methylamphetamine) in patients with severe PTSD showed acceptable efficacy and safety profile. Evidence has recently emerged for the efficacy of psilocybin in major depressive disorder (MDD). Psilocybin is a psychoactive alkaloid produced by more than 200 mushroom species with some evidence of rapid-onset antidepressant properties. In recent psilocybin clinical trials, treatment requirements for MDD patients ranged from a single dose to monthly dosing with similar efficacy and safety. While psilocybin and MDMA offer hope for patients without other treatment options, it is estimated that they benefit only 5-10% of patients in need.
[0005] Identifying manipulations that reopen critical periods has become a priority for translational neuroscience. Many neuropsychiatric disease states are believed to be developmentally associated with the closure of a "critical period," an early interval in the life span when the nervous system is more sensitive to healthy (or harmful) environmental stimuli required for proper circuit organization and learning. Even when optimal conditions are restored, the closure of the critical period limits the brain's ability to adapt. Agonists of the 5-hydroxytryptamine (5-HT) serotonin receptor family, including MDMA, DMT, and mescaline, increase oxytocin levels (which are involved in social function and animal models show that they can open a critical window for cortical function), thereby allowing learning of new behavioral responses. These oxytocin receptors in the nucleus accumbens (NAc) activate 5-HT in the medium spiny neurons of the dorsal raphe nucleus. 1B Receptor activation, blocking 5-HT 1B Receptors block social reward learning.
[0006] Mescaline (3,4,5-trimethoxyphenethylamine) is an ancient precursor to the modern synthetic phenethylamine 2-CB (2,5-dimethoxy-4-bromophenethylamine), derived from the crown-button of the peyote cactus native to Mexico and southwestern Texas. After a methylation step, mescaline closely resembles the catecholamine signaling molecules dopamine and norepinephrine; its psychoactive properties may result from this structural similarity. Most of the novel psychoactive compounds still fall into familiar neurochemical classes and have overlapping pharmacology with their typical predecessors. It has long been assumed that these agents, especially the phenylalanamines, are most selective for two of the more than 50 neurotransmitter receptor subclasses: 5-HT and 6-HT. 2A and 5-HT 2C .
[0007] MBDB (N-methyl-1-(1,3-benzodioxol-5-yl)-2-aminobutane) is the α-ethyl analog of MDMA, synthesized in the 1980s by several drug chemistry groups. MBDB is the prototypical member of the "entactogen" class, currently not Schedule I in the United States, and combines two structural features that weaken binding at monoamine receptors: N-methylation and α-ethylation. MBDB quickly became a recreational drug, incorporated with MDMA and other synthetic cathinones as a component of "Ecstasy" pills. In two retrospective reports of multiple drug overdose deaths associated with MBDB, in which alcohol and marijuana levels were also measured, blood concentrations of 0.435 and 1.2 mg / L were measured. In a meta-analysis of MDMA overdose deaths, 13 of the 77 deaths directly attributable to the toxic effects of MDMA alone had blood concentrations measured in the range of 0.478-53.9 mg / L, which is comparable to the presumed toxic MBDB levels. In addition, in the animal model, (±)-MBDB.HCl (25 mg / kg) was injected IP every 12 hours for 4 days, with (±)-MDMA.HCl (20 mg / kg) used for comparison. Based on the loss of 5-HT / 5-HIAA uptake sites, the multiple-dose regimen used in this study significantly destroyed 55% to 60% of serotonin-activated terminals in the cortex and hippocampus 2 weeks after treatment without significantly altering catecholamines or their metabolites. These results show a reduction in indices related to serotonin-activated function after multiple MBDB administrations. This neurotoxic effect is slightly less than that found with behaviorally equivalent doses of MDMA.
[0008] Synthetic cathinones, such as methyl ketone (3,4-methylenedioxy-N-methylcathinone), are psychomotor stimulants that exert their effects by altering the function of plasma membrane transport proteins for serotonin, dopamine, and norepinephrine. The potency of individual cathinones on each of the three monoamine neurotransmitter pathways may vary. Naturally occurring cathinones are alkaloids that are structurally similar to amphetamines and were originally extracted from fresh leaves of the khat plant, Catha edulis, or khat, chewed by people in East Africa and the Arabian Peninsula. Synthetic structural modifications of cathinones have produced a variety of "designer" derivatives that are often sold as "bath salts" through illegal distribution. These cathinone derivatives (chemically classified as β-ketoamphetamines) include methyl ketone, ethyl ketone, butyl ketone, mephedrone, and 3,4-methylenedioxypyrovalerone (MDPV), and act synergistically at the human dopamine transport protein. Cathinones and other related classes of phenethylamines all behave as central nervous system (CNS) stimulants; however, cathinones are generally less potent than the corresponding phenethylamine analogs because the β-keto group produces a more polar molecule with a lower ability to cross the blood-brain barrier.
[0009] Methylone has an affinity for vesicular monoamine transporter 2 (VMAT2) that is approximately 13-fold lower than that of MDMA. However, there is some mixed evidence: analysis of plasma membrane and vesicular monoamine transporters in a mouse locomotor activity model found methylone to be a more potent inhibitor of 5-HT and dopamine uptake than MDMA. Following intraperitoneal administration in rats, methylone reaches peak brain and serum concentrations within 15-30 minutes with a half-life of approximately 1-2 hours. In contrast, the half-life of MDMA is in the 5-7 hour range, depending on the animal model used and the conditions of administration.
[0010] In humans, SSRIs also attenuate or prevent the therapeutic effects of MDMA due to substrate competition: side effects such as increased blood pressure (BP) and hyperthermia are partly attributed to the interaction of MDMA with serotonin carriers. This is another important consideration when considering use as a rapid-acting antidepressant or augmentation therapy. Previous studies have found an association between MDMA use and symptoms of depression and anxiety. Given that people who choose to use MDMA have pre-existing psychiatric problems, the difficulty of assessing a causal relationship or link between MDMA and depression is increased. A meta-analysis detected an association between MDMA use and self-reported depressive symptoms. A range of pharmacogenetic variations in MDMA metabolism also increases the risk of depression in a significant number of patients.
[0011] Animal studies addressing the psychological effects of MDMA tested a 10 mg / kg dose in rats for 10 days; measures of anxiety-like behavior, such as open-field walking, indicated an increase in anxiety phenotypes after 3 months. Rats were given 4 doses of 5 mg / kg of MDMA over 4 hours for 2 consecutive days, which weakened responses (active and passive) in the forced swim test and increased immobility for up to 12 weeks after MDMA exposure, indicating possible long-term negative behavioral changes. Fluoxetine treatment reversed MDMA-induced anxiety in the emergence test and immobility duration in the forced swim test, but did not show an effect on the social interaction test. This study also analyzed the postmortem content of 5-HT and its metabolite 5-hydroxyindoleacetic acid (5-HIAA), both of which were reduced in the cortical areas of rats treated with MDMA. Fluoxetine treatment did not have a great effect on the 5-HT content of rats pretreated with MDMA, but significantly reduced 5-HIAA content in all brain parts examined. This can be explained as a chronic depletion of 5-HT induced by MDMA, leading to an anxious or depressive phenotype.
[0012] Other mechanisms include acute MDMA-induced 5-HT release from serotonin-activated peripherals, and inhibition of 5-HT reabsorption, which results in a significant depletion of both 5-HT and 5-HIAA. This has been reported in human postmortem brain tissue and in vivo from cerebrospinal fluid (CSF) measurements. Following the monoamine theory of depression, this data is discouraging, but the research is mixed to some extent: evidence highlights the differences between acute and chronic MDMA pharmacology. Although in acute situations, MDMA works to increase 5-HT availability, suggesting rapid onset antidepressant properties and positive changes to mood, this short-lived effect may be accompanied by subsequent depletion of 5-HT. There is anecdotal human experience supporting the depletion of 5-HT stores at doses that will be used therapeutically.
[0013] Reduced levels of 5-HT and its metabolites in brain tissue and CSF, as assessed in vivo, are also interpreted as indicating that MDMA is neurotoxic. Incidentally, low serotonin transporter (SERT) density is also associated with depression. Given the reduced SERT density in animal literature, a simple interpretation is that repeated exposure to MDMA in humans, even at moderate amounts, results in damage to the 5-HT neuronal terminals that innervate the cortex. In addition, changes in mood, cognition, and impulse control associated with these changes may help maintain MDMA use.
[0014] These and other discrepancies in the neurotoxicity data for MDMA remain unresolved, making it unlikely that MDMA will be explored as a mainstream antidepressant; especially as the 5-HT neurotransmitter circuit is implicated in both depression pathophysiology and MDMA neurotoxicity. In the recent PTSD Phase 2 MDMA trial, there were cases of depression recorded as adverse events at doses of 125 mg and 150 mg, some of which persisted during long-term follow-up. Anxiety and severe suicidal ideation were also recorded. And before it progressed to Phase 3, the hypothesis that MDMA had potential efficacy as a fast-acting antidepressant was explored. However, MDMA, psilocybin, and the other typical hallucinogens mentioned have at least the following limitations in reaching the hundreds of millions of people suffering from refractory neuropsychiatric diseases:
[0015] 1) Safety: Given its potent serotonergic agonism, it is contraindicated in patients taking SSRIs and many other psychotropics due to the risk of serotonin syndrome. This would prevent many, if not most, patients with neuropsychiatric disorders from accessing these agents. In addition, MDMA causes various forms of arrhythmias and dilated cardiomyopathy with chronic use, potentially leading to ventricular fibrillation and cardiac arrest, and is therefore contraindicated in pre-existing dysrhythmias or lung disease.
[0016] 2) Combinations: Patients with refractory conditions have often tried SSRIs / serotonin-norepinephrine reuptake inhibitors (SNRIs) / tricyclic antidepressants (TCAs) / etc. It takes a minimum of 6 weeks to wean patients off SSRIs and other antidepressant medications. Therefore, the development of psychotropic analogs that minimize deleterious interactions and increase in therapeutic efficacy would be a compelling benefit to patients in need. It would be unfortunate if the people who would benefit most from psychotropic medications were hampered by their past or current treatment regimens.
[0017] 3) Care delivery / ease of use: Psychoactive treatments are ideally self-administered at home or with minimal supervision. Access to MDMA and psilocybin is limited by the amount of time required for each administration, the number of hours of provider and safe caregiver time, and training and licensing requirements. MDMA and psilocybin also have a long administration phase (up to 8 hours) in addition to the preparation and integration psychotherapy phases. Likewise, ketamine via IV infusion requires a 3-4 hour clinical visit and physician administration and supervision, along with in-depth psychotherapy.
[0018] 4) Patient consent: Many patients are reluctant to undergo treatment with typical hallucinogens and entactogens such as psilocybin and MDMA. For these treatments, clinical outcomes can depend on profound subjective experiences that are often challenging, uncomfortable, or terrifying.
[0019] Therefore, CNS drugs, including antidepressants and PTSD treatments, are needed, which have mainstream potential, better safety and efficacy, faster onset profiles, fewer drug interactions, and / or are more effective in combination therapy. The prevalence of any mental illness (AMI) in American adults is greater than 50 million, representing> 20% of the population. The gap between the burden of disease and effective treatment is widening. Regardless of adverse effects, Wellbutrin (bupropion), an atypical triple reuptake inhibitor (norepinephrine-dopamine reuptake inhibitor, nicotinic receptor antagonist), is still one of the most widely prescribed antidepressants (24 million prescriptions in 2018). Bupropion is usually used in conjunction with SSRI, and it has also been shown to have positive results in treating anxiety associated with depression compared with sertraline and fluoxetine. It is reported that, in addition to other drugs for the treatment of panic disorder, bupropion is used outside the drug approval label. However, side effects of bupropion include a >23% increased risk of congenital heart defects in the first trimester and a range of neurologic side effects such as anxiety, abdominal pain, irritability, insomnia, headache / migraine, nausea / vomiting, constipation, tremor, dizziness, excessive sweating, blurred vision, tachycardia, confusion, rash, hostility, heart arrhythmia, and hearing impairment.
[0020] Therefore, there is a need for new psychopharmacological agents that can address these and other limitations and / or reach a wider range of patients with neuropsychiatric pathologies. Such neuropsychiatric pathologies include many difficult-to-treat mood, anxiety, and personality disorders, such as depression and PTSD, as well as: fibromyalgia, suicidal ideation, substance use disorders (SUD), eating disorders, borderline personality disorder (BPD) and other personality disorders, obsessive-compulsive disorder (OCD), palliative care / end-of-life anxiety, existential distress, chronic pain syndromes, body dysmorphia, phobias, social anxiety in autistic adults, and even sleep regulation. Summary of the invention
[0021] In one aspect, provided herein is a method for treating and / or preventing a neuropsychiatric disorder and / or improving symptoms thereof in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of methyl ketone (3,4-methylenedioxy-N-methylcathinone). In some embodiments, the methyl ketone dose is within the range of 0.08-4 mg / kg. In some embodiments, the methyl ketone dose is within the range of 0.8-5 mg / kg. In some embodiments, the methyl ketone dose is within the range of 0.8-30 mg / kg. In some embodiments, the methyl ketone dose is within the range of 5-250 mg. In some embodiments, the methyl ketone dose is less than 50 mg. In some embodiments, the methyl ketone dose is within the range of 5-50 mg. In some embodiments, the methyl ketone dose is less than 25 mg. In some embodiments, the methyl ketone dose is within the range of 5-25 mg. In some embodiments, the methyl ketone dose is within the range of 50-350 mg. In some embodiments, the methyl ketone dose is within the range of 50-500 mg. In some embodiments, the methyl ketone dose is within the range of 50-1,000 mg. In some embodiments, an initial dose of methyl ketone (e.g., 50-500 mg) is administered, which is then reinforced by administering a second methyl ketone dose (e.g., an additional 25-250 mg methyl ketone) 30 minutes to 4 hours later. In some embodiments, methyl ketone is administered, for example, in a single dose or according to the aforementioned dosing schedule, once a week or twice a week or more (up to daily dosing) or twice or three times a day. In some embodiments, methyl ketone is administered in the form of an extended release or sustained release formulation, for example, to achieve a dosing regimen disclosed herein, and 50 mg to 1 g is released to those patients according to a set schedule based on the indications treated in the patient. In some embodiments, the subject has suicidal tendencies. In some embodiments, the neuropsychiatric disease is refractory. In some embodiments, methyl ketone is used in combination with additional therapies for neuropsychiatric diseases. In some embodiments, the additional therapy is psychotherapy. In some embodiments, the additional therapy comprises administering one or more additional psychoactive agents to the subject. In some embodiments, the additional psychoactive agent is selected from the group consisting of: selective serotonin reuptake (SSRI), tricyclic antidepressants (TCA), monoamine oxidase inhibitors (MAOI), serotonin-norepinephrine reuptake inhibitors (SNRI), serotonin-norepinephrine-dopamine reuptake inhibitors (SDNRI) and antianxiety agents. In some embodiments, the neuropsychiatric disease is depression. In some embodiments, depression is selected from the group consisting of: intrusive mood disorder; major depressive disorder; single episode and recurrence; persistent depressive disorder (dysthymia); premenstrual depression; substance / drug-induced depression; depression due to another medical condition; other specified depression; unspecified depression; and combinations thereof. In some embodiments, the neuropsychiatric disease is post-traumatic stress disorder (PTSD).In some embodiments, the neuropsychiatric disease is acute stress disorder. In some embodiments, the neuropsychiatric disease is fibromyalgia. In some embodiments, the neuropsychiatric disease is a mood disorder. In some embodiments, the neuropsychiatric disease is an anxiety disorder. In some embodiments, the neuropsychiatric disease is an eating disorder. In some embodiments, the neuropsychiatric disease is a personality disorder (PD). In some embodiments, the personality disorder is selected from the group consisting of: borderline personality disorder (BPD), avoidant personality disorder (AvPD), antisocial personality disorder (AsPD), schizotypal personality disorder, other anxiety and panic disorders, specific personality disorders, impulse disorders, gender identity disorders, paraphilias, other sexual disorders, adult personality and behavioral other disorders, adult personality and behavioral unspecified disorders, personality and behavioral disorders attributed to known physiological conditions. In some embodiments, the subject with PD also suffers from depression.
[0022] In another aspect, provided herein is a method for treating and / or preventing a neuropsychiatric disorder and / or ameliorating symptoms thereof in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of 2C-B (4-bromo-2,5-dimethoxyphenethylamine). In some embodiments, the 2C-B dose is in the range of 0.08-4 mg / kg. In some embodiments, the 2C-B dose is in the range of 0.8-5 mg / kg. In some embodiments, the 2C-B dose is in the range of 0.8-30 mg / kg. In some embodiments, the 2C-B dose is in the range of 5-250 mg. In some embodiments, the 2C-B dose is less than 50 mg. In some embodiments, the 2C-B dose is in the range of 5-50 mg. In some embodiments, the 2C-B dose is less than 25 mg. In some embodiments, the 2C-B dose is in the range of 5-25 mg. In some embodiments, the 2C-B dose is in the range of 50-350 mg. In some embodiments, the 2C-B dose is in the range of 50-500 mg. In some embodiments, the 2C-B dose is in the range of 50-1,000 mg. In some embodiments, an initial dose of 2C-B (e.g., 50-500 mg) is administered, which is then reinforced by administering a second 2C-B dose (e.g., an additional 25-250 mg 2C-B) 30 minutes to 4 hours later. In some embodiments, 2C-B is administered, for example, in a single dose or according to the aforementioned dosing schedule, once a week or twice a week or more (up to daily dosing) or twice or three times a day. In some embodiments, 2C-B is administered in the form of an extended release or sustained release formulation, for example to achieve the dosing regimen disclosed herein, and 50 mg to 1 g is released to those patients according to a set schedule based on the indication treated in the patient. In some embodiments, the neuropsychiatric disease is somatic symptom disorder. In some embodiments, the somatic symptom disorder is selected from the group consisting of: disease anxiety disorder, conversion disorder (functional neurological symptom disorder), psychological factors affecting other medical conditions, factitious disorders, other specific somatic symptoms and related disorders, unspecified somatic symptoms and related disorders, and combinations thereof. In some embodiments, the neuropsychiatric disease is fibromyalgia. In some embodiments, the neuropsychiatric disease is depression. In some embodiments, depression is selected from the group consisting of: intrusive mood disorder; major depressive disorder; single episode and recurrence; persistent depressive disorder (dysthymia); premenstrual dysphoric disorder; substance / drug-induced depression; depression attributed to another medical condition; other specified depression; unspecified depression; and combinations thereof. In some embodiments, the neuropsychiatric disease is post-traumatic stress disorder (PTSD). In some embodiments, the neuropsychiatric disease is acute stress disorder. In some embodiments, the neuropsychiatric disease is a mood disorder. In some embodiments, the neuropsychiatric disease is an anxiety disorder. In some embodiments, the neuropsychiatric disease is an eating disorder. In some embodiments, the subject is suicidal.In some embodiments, the neuropsychiatric disorder is refractory. In some embodiments, 2C-B is used in combination with an additional therapy for the neuropsychiatric disorder. In some embodiments, the additional therapy is psychotherapy. In some embodiments, the additional therapy comprises administering one or more additional psychotropic agents to the subject. In some embodiments, the additional psychotropic agent is selected from the group consisting of: SSRI, TCA, MAOI, SNRI, SDNRI, and antianxiety agents.
[0023] In another aspect, provided herein is a method for treating and / or preventing a neuropsychiatric disorder and / or ameliorating symptoms thereof in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of MBDB (N-methyl-1-(1,3-benzodioxol-5-yl)-2-aminobutane). In some embodiments, the MBDB dose is in the range of 0.08-4 mg / kg. In some embodiments, the MBDB dose is in the range of 0.8-5 mg / kg. In some embodiments, the MBDB dose is in the range of 0.8-30 mg / kg. In some embodiments, the MBDB dose is in the range of 5-250 mg. In some embodiments, the MBDB dose is less than 50 mg. In some embodiments, the MBDB dose is in the range of 5-50 mg. In some embodiments, the MBDB dose is less than 25 mg. In some embodiments, the MBDB dose is in the range of 5-25 mg. In some embodiments, the MBDB dose is in the range of 50-350 mg. In some embodiments, the MBDB dose is in the range of 50-500 mg. In some embodiments, the MBDB dose is in the range of 50-1,000 mg. In some embodiments, an initial dose of MBDB (e.g., 50-500 mg) is administered, which is then boosted 30 minutes to 4 hours later by administering a second dose of MBDB (e.g., an additional 25-250 mg MBDB). In some embodiments, MBDB is administered, for example, in a single dose or according to the aforementioned dosing schedule, once a week or twice a week or more (up to daily dosing) or twice or three times a day. In some embodiments, MBDB is administered in an extended release or sustained release formulation, for example to achieve the dosing regimen disclosed herein, and 50 mg to 1 g is released to those patients on a set schedule depending on the indication being treated in the patient. In some embodiments, the neuropsychiatric disease is depression. In some embodiments, depression is selected from the group consisting of: intrusive mood dysregulation disorder, major depressive disorder, single and recurrent episodes, persistent depressive disorder (dysthymia), premenstrual dysphoric disorder, substance / drug-induced depression, depression due to another medical condition, other specified depression, unspecified depression, and combinations thereof. In some embodiments, the neuropsychiatric disease is anxiety.In some embodiments, the anxiety disorder is selected from the group consisting of: generalized anxiety disorder; panic disorder; panic attack; phobic anxiety disorder; illness anxiety disorder; other non-psychotic mental disorders of dissociative, stress-related, somatoform; acute stress reaction; transient adjustment reaction; neurasthenia; psychophysiological abnormalities; obsessive-compulsive disorder; reaction to severe stress and adjustment disorder; separation anxiety disorder; intermittent paroxysmal anxiety; selective mutism; specific phobia; social anxiety disorder (social phobia); agoraphobia; substance / drug-induced anxiety disorder; anxiety disorder due to another medical condition; pregnancy and childbirth anxiety; antenatal (pre-delivery) pregnancy anxiety; postpartum anxiety; animal phobia; spider phobia; other animal phobias; natural environmental phobias; thunderstorm phobia; blood phobia; injection and infusion phobia; other medical care phobias; fear of injury; situational phobias; claustrophobia; acrophobia; other unspecified anxiety disorders; body dysmorphia; hoarding disorder; trichotillomania (hair pulling disorder); skin picking disorder; and combinations thereof. In some embodiments, the subject has suicidal tendencies. In some embodiments, the neuropsychiatric disease is refractory. In some embodiments, the neuropsychiatric disease is post-traumatic stress disorder (PTSD). In some embodiments, the neuropsychiatric disease is acute stress disorder. In some embodiments, the neuropsychiatric disease is fibromyalgia. In some embodiments, MBDB is used in combination with an additional therapy for neuropsychiatric disease. In some embodiments, the additional therapy is psychotherapy. In some embodiments, the additional therapy comprises administering one or more additional psychotropic agents to the subject. In some embodiments, the additional psychotropic agent is selected from the group consisting of: SSRI, TCA, MAOI, SNRI, SDNRI and antianxiety agent.
[0024] Other features and advantages of the present invention will become apparent from the following detailed description examples and drawings. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments, are given by way of illustration only, as various changes and modifications will become apparent to those skilled in the art from this detailed description. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] The following drawings form part of this specification and are included to further demonstrate certain aspects of the present disclosure, and the invention of the present disclosure may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
[0026] Figure 1 A baseline symptom checklist of symptoms occurring in 2 or more of the 28 patients included in Group 2 of Example 4 is presented.
[0027] Figure 2Baseline disease severity in Group 2 of Example 4 is shown.
[0028] Figure 3A-3B exhibit( Figure 3A )MDD subset and ( Figure 3B )The magnitude of improvement in Group 2 for subjects in the PTSD subset.
[0029] Figure 4A-4B The patient of Example 5 is shown in ( Figure 4A ) baseline disease severity and ( Figure 4B ) to improve the value.
[0030] Figures 5A-5C Methylone has a robust antidepressant-like effect in the forced swim test. Figure 5A )Stay still(F (5,34) =59.05, p<0.0001), ( Figure 5B )Swimming(F (5,34) =28.72, p<0.0001) or ( Figure 5C )Climb(F (5,34) =3.195, p<0.05) time. 24 hours before the test, the rats were allowed to swim for 15 minutes. Fluoxetine (10 mg / kg, IP) was administered 1, 5 and 23.5 hours before the test. Methylone (5, 15, 30 mg / kg, IP) was administered 30 minutes before the test. All data are presented as mean + / - SEM. One-way analysis of variance (ANOVA) and post hoc Tukey's test. *p<0.05 relative to vehicle 1× group; ****p<0.0001 relative to vehicle 1× group; ++++ p<0.0001 versus vehicle 3× group; N=6-8 per group.
[0031] Figure 6 : Methylone outperforms other antidepressants in the forced swim test.
[0032] Figure 7 A-7C:2C-B has a rapid onset of antidepressant-like effects in the forced swim test. Quantification of time spent in a 5-min rat forced swim test ( Figure 7 A) No movement (F (5,34) =17.73, p<0.0001), ( Figure 7 B) Swimming (F (5,34) =16.49, p<0.0001) or ( Figure 7 C) Climbing (5,34)=4.984, p<0.001) time. 24 hours before testing, rats were allowed to swim for 15 minutes. Fluoxetine (10 mg / kg, IP) was administered 1, 5 and 23.5 hours before testing. 2C-B (2.5, 10, 20 mg / kg, IP) was administered 30 minutes before testing. All data are presented as mean + / - SEM. One-way analysis of variance and post hoc Tukey test. **p<0.01 relative to vehicle 1× group; ****p<0.0001 relative to vehicle 1× group; ++++ p < 0.0001 relative to the vehicle 3× group; +++ p<0.001 vs. vehicle 3× group, N=6-8 per group.
[0033] Figures 8A-8D : Methylone has robust antidepressant-like effects in the forced swim test. Fig. 8A ) Schematic diagram of the experimental design. Quantification of time spent in a 5-min forced swim test in rats ( Figure 8B )Stay still(F (4,31) =17.05, p<0.0001), ( Figure 8C )Climbing (4,31) =5.786, p<0.01) or ( Fig.8D )Swimming(F (4,31) =6.063, p<0.01) time. Rats were allowed to swim for 15 minutes 24 hours before testing. Fluoxetine (10 mg / kg, IP) was administered 1, 5 and 23.5 hours before testing. Methylone (5 or 15 mg / kg, IP) was administered 30 minutes before testing. All data are presented as mean + / - SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 relative to vehicle control group; relative to fluoxetine treatment group, + p<0.05, ++ p<0.01; a p = 0.06 relative to the fluoxetine-treated group; b p=0.08 relative to vehicle control group. N=6-8 per group.
[0034] Figures 9A-9C :Methylketone improves fear extinction recall in a mouse model of PTSD. Fig.9A ) Schematic diagram of the experimental design. Single CS-US (tone-shock) pairing on day 1, followed by 6 CS presentations in a novel condition (condition B). Methylone or saline vehicle was injected 30 minutes before extinction training on day 2. On day 3, the time spent freezing due to the CS was quantified. ( Fig. 9BCompared with saline, methylketone significantly reduced the immobility time (t (26) =2.350, p<0.05). Fig. 9C ) No movement changes were observed on day 3 (t (26) =1.073, p>0.05). Data are mean + / - SEM. N=12 for methyl ketone group (30 mg / kg, IP) and N=16 for saline control group. *p<0.05.
[0035] Figures 10A-10B : MBDB improves fear extinction in a PTSD mouse model. A single CS-US (tone-shock) pairing was presented on day 1, followed by 6 conditioned stimulus (CS) presentations in a novel context (Context B). MBDB or saline vehicle was injected 30 minutes before extinction training on day 2. On day 2, the time spent immobilizing due to the CS was quantified. ( Fig. 10A ) MBDB significantly reduced the immobility time during the first extinction training trial on day 2 compared to saline control (t(24)=3.095, p<0.01). Fig. 10B ) MBDB also induced a small but significant increase in locomotor activity on day 2 (t(24)=2.874, p<0.01). Data are mean + / - SEM. N=10 for MBDB group (5 mg / kg, IP) and N=16 for saline control group. **p<0.01 relative to vehicle control group.
[0036] Figures 11A-11B : Methylone reduces anxiety and increases locomotion in the open space test. Rats received a single injection of methylone 30 minutes before a 30-minute test in the open space. ( Fig.11A ) The time spent in the center demonstrated the anxiolytic effect of methylone compared with vehicle-treated controls (F (3,20) =7.139, p<0.01). Fig. 11B ) Total distance traveled showed increased locomotion after medium and high doses of methylone (F (3,20) =6.209, p<0.01). Data are mean + / - SEM. N=6 per group. *p<0.05; **p<0.01 relative to vehicle control group.
[0037] Fig.12 A-12D: ( Fig.12 A) Schematic diagram showing the experimental design. Methylone or saline (vehicle) was administered at the indicated time points. Immobility ( Fig.12 B) Climbing Fig.12 C) or swimming ( Fig.12D) Quantification of the percentage of time spent. Data are presented as mean ± SEM. **p < 0.01, ****p < 0.0001 compared to vehicle control group, ns = not significant compared to vehicle control group (p = 0.6); Tukey post hoc test; N = 6 for methyl ketone group; N = 8 for vehicle control group.
[0038] Fig.13 A-13C: MBDB or vehicle was administered 30 minutes before the FST test. It shows that during the 5-minute test, immobility ( Fig.13 A) Climbing Fig.13 B) or swimming ( Fig.13 C) Quantification of the percentage of time spent. Data are presented as mean ± SEM. **p < 0.01, ****p < 0.0001 compared to vehicle control group; Tukey post hoc test; N = 7 per group.
[0039] Fig.14 :In the presence or absence of methyl ketone, the synaptosomes of rat brain 3 H]5HT uptake.
[0040] Fig.15 :[ 3 [H] 5HT binds to membranes expressing 5HT2B receptors. DETAILED DESCRIPTION
[0041] The inventors identified methylketone as a pharmaceutical agent useful for treating CNS disorders. Methylketone (3,4-methylenedioxy-N-methylcathinone; also known as "βk-MDMA") is a close structural analog of synthetic empathogenic cathinones and MDMA, but with a >50% shorter half-life. There are no FDA-registered clinical trials of its efficacy or safety profile after the US DEA placed it in Class I restricted status in 2010. Methylketone and MDMA are similar to amphetamines and are agonists of 5-HT2 family serotonin receptors. In vitro release analysis using rat brain synaptosomes demonstrated that methylketone is a non-selective substrate for plasma membrane monoamine transporters and receptors.
[0042] Methyl ketone acts as a mixed reuptake inhibitor / releaser and has a 3-fold lower affinity for serotonin transporters than MDMA, but similar affinity for norepinephrine and dopamine transporters. This weakened serotonin activation pathway dominance is one reason why its efficacy as an antidepressant is not expected. In addition, the "down" effect from amphetamines (including MDMA or synthetic cathinones such as methyl ketone) includes severe depression and fatigue. Methyl ketone produces extensive depletion of 5-HT and serotonin transporter 5-HTT levels in rats, similar to a depressive neurological state. Depression has also been reported in humans using methyl ketone. Other adverse effects include anxiety, anorexia, loss of reality / depersonalization, impaired short-term memory, psychosis, hallucinations, suicidal ideas, irritability, motivation inhibition, slowing of thinking, awakening, involuntary tremors, grinding teeth in sleep, jaw clenching, trismus, and hand and gait instability.
[0043] In summary, animal and human data do not indicate the potential medical use of methylketone as a treatment for CNS disorders, including depression and PTSD. Surprisingly, methylketone (with the (lowest) 5-HT agonism in its synthetic cathinone class) will be suitable for indications identified by the inventors for patients who are unresponsive, refractory, contraindicated or opposed to current standard care. This will include administering methylketone alone or in combination with SSRIs, TCAs, MAOIs, SNRIs, SDNRIs or antianxiety agents such as benzodiazepines, beta-blockers, alpha-blockers and buspirone.
[0044] The inventors have found that methylketone has mainstream potential as a CNS drug, including as an antidepressant or as a treatment for PTSD or as an antianxiety agent. Compared to other treatments, methylketone has advantages over current therapies and other therapies in development: better efficacy-safety ratio, faster onset profile, fewer drug interactions, more effective combination therapy, more frequent adjunct in individual or group psychotherapy. Methylketone also causes fewer side effects after longer periods or long-term use, unlike the symptoms of SSRI tolerance, because the efficacy gradually decreases for a large proportion of patients. Symptoms of SSRI tolerance include fatigue, loss of motivation, tiredness, sleep disorders, restless legs syndrome, irritability and depressed mood.
[0045] The inventors have further identified 2C-B (2,5-dimethoxy-4-bromophenethylamine) as an agent useful for treating and providing symptom relief for somatic symptom disorder (SSD), depression, PTSD and other central nervous system (CNS) disorders, but particularly fibromyalgia, a widespread musculoskeletal pain syndrome with symptoms of fatigue, sleep, memory and mood disturbances. Treatments for fibromyalgia, such as the SNRIs duloxetine and milnacipran, are generally outweighed by their potential harms, and only a minority of fibromyalgia patients experience significant symptom relief without adverse events.
[0046] 2C-B is reported to be a 5-HT 2A Phenylethylamine is a partial agonist of the 5-HT receptor, but we hypothesize that it is applicable to 2A Pathophysiology. In vitro and in vivo models suggest that it acts as a mixed 5-HT 2A Antagonists, and 5-HT 2B and 5-HT 2C Partial agonist (specific for receptors expressed on apical dendrites of neocortical pyramidal cells in layer V). Due to its adverse profile and abuse potential, it is a Schedule 1 drug, as a large number of hospitalizations have been associated with 2C-B ingestion via toxicology studies.
[0047] No serious adverse reactions were found in human open-label studies of experienced drug users who self-administered 2C-B at doses ranging from 10 to 20 mg. At doses above 20 mg, 2C-B users reported more euphoria, kaleidoscopic visions, and perceptual distortions.
[0048] Chronic psychiatric disorders often have a common core of refractory symptoms that respond favorably to psychoactive drugs via complex pharmacological effects that can be further modulated by psychotherapy. Patients experience multiple coexisting symptoms that are related to each other, have independent or parallel temporal dimensions or severity levels, and may have common underlying mechanisms. Clusters can also be viewed as "symptom endophenotypes" that span syndromes and disorders via neurobiological correlates of brain circuits and neurotransmitters.
[0049] Without wishing to be bound by theory, the inventors hypothesize that 2C-B has a compelling neurobiological rationale for treating SSD, depression, anxiety, PTSD, and comorbid conditions via an acute somatic conversion phenomenology and a persistent psychoactive pharmacological and physiological effect profile. SSD, including fibromyalgia, is generally a diagnosis of exclusion, with chronic somatic symptoms of uncertain biological or medical cause. The named entities under SSD in DSM-5 are illness anxiety / hypochondriasis, functional neurological / conversion disorders, pain disorders (under which fibromyalgia is classified), body dysmorphic disorder, and somatoform disorders of "unspecified type." It is often comorbid with mood and affective disorders, which may include mood disturbance clusters and neuropsychological discomfort clusters. Fibromyalgia patients can be successfully treated with lower doses of 2C-B in the range of 1-24 mg and in combination with other psychoactive drugs for CNS disorders.
[0050] The inventors have further identified MBDB (N-methyl-1-(1,3-benzodioxol-5-yl)-2-aminobutane) as an agent useful for treating and providing symptomatic relief of generalized anxiety disorders, or as an antidepressant. Animal and human data do not indicate potential medical use of MBDB as a treatment for CNS disorders or otherwise. No serious adverse effects were found in experimental drug users who self-administered MBDB at doses ranging from 100 to 300 mg under supervision in a controlled environment. In summary, MBDB can be used as an anxiolytic, and this therapeutic effect can be reliably assessed using measures such as GAD-7 or the Generalized Anxiety Disorder Severity Scale (GADSS).
[0051] The diseases, conditions and disorders listed herein are described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) published by the American Psychiatric Association or the International Classification of Diseases (ICD) published by the World Health Organization.
[0052] Illness, condition, disease or disorder includes, but is not limited to, the following and all intermediate ICD-10 codes within the definition:
[0053] F01-F09 Mental disorders attributable to known physiological conditions
[0054] F01 Vascular dementia; F02 Dementia in other diseases classified elsewhere; F03 Unspecified dementia; F04 Amnesic disorder attributed to a known physiological condition; F05 Delirium attributed to a known physiological condition; F06 Other mental disorders attributed to a known physiological condition; F07 Personality and behaviour disorders attributed to a known physiological condition; F09 Unspecified mental disorder attributed to a known physiological condition.
[0055] F10-F19 Mental and behavioral disorders attributable to psychoactive substance use
[0056] F10 Alcohol-related disorder; F11 Opioid-related disorder; F12 Cannabis-related disorder; F13 Sedative, hypnotic, or anxiolytic-related disorder; F14 Cocaine-related disorder; F15 Other stimulant-related disorder; F16 Hallucinogen-related disorder; F17 Nicotine dependence; F18 Inhalant-related disorder; F19 Other substance-related disorder. Caffeine-related disorder, Caffeine intoxication, Caffeine withdrawal, Other caffeine-induced disorder, Substance-related disorder, Non-substance-related disorder, Gambling disorder, Neurocognitive disorder, Delirium, Other specified delirium, Unspecified delirium, Severe and mild neurocognitive disorder, Severe neurocognitive disorder, Mild neurocognitive disorder, Severe or mild neurocognitive disorder attributed to Alzheimer's disease, Severe or mild neurocognitive disorder, Frontotemporal type, Lewy body type, Severe or mild neurocognitive disorder, Vascular neurocognitive disorder, Severe or mild neurocognitive disorder attributed to traumatic brain injury, Substance / medication-induced severe or mild neurocognitive disorder, Severe or mild neurocognitive disorder attributed to HIV infection, Severe or mild neurocognitive disorder attributed to prion disease, Severe or mild neurocognitive disorder attributed to Parkinson's disease, Severe or mild neurocognitive disorder attributed to Huntington's disease Disease), severe or mild neurocognitive disorder attributable to another medical condition, severe or mild neurocognitive disorder attributable to multiple etiologies, or unspecified neurocognitive disorder.
[0057] F20-F29 Schizophrenia, schizotypal disorder, delusional disorder and other non-emotional psychotic disorders
[0058] F20 Schizophrenia; F21 Schizotypal disorder; F22 Delusional disorder; F23 Brief psychotic disorder; F24 Shared psychotic disorder; F25 Schizoaffective disorder; F28 Other mental disorders not attributable to a substance or known physiological condition; F29 Unspecified mental illness not attributable to a substance or known physiological condition.
[0059] F30-F39 Emotional disorders
[0060] F30 Manic episode; F31 Bipolar disorder; F32 Major depressive disorder, single episode; F33 Major depressive disorder, recurrent; F34 Persistent mood [affective] disorder; F39 Unspecified mood [affective] disorder.
[0061] Intrusive mood disorder, persistent depressive disorder (dysthymia), premenstrual dysphoric disorder, substance / medication-induced depression, depression attributed to another medical condition, other specified depression, unspecified depression, and treatment-resistant depression.
[0062] F40-F48 Other non-psychotic mental disorders, anxiety, dissociative, stress-related, somatoform
[0063] F40 Phobia and anxiety disorders; F41 Other anxiety disorders; F42 Obsessive-compulsive disorder; F43 Reaction to severe stress and adjustment disorder; F44 Dissociative and conversion disorders; F45 Somatoform disorders; F48 Other non-psychotic mental disorders.
[0064] Anxiety disorders: separation anxiety disorder, selective mutism, specific phobia, social anxiety disorder (social phobia), panic disorder, panic attack (Specifier), agoraphobia, generalized anxiety disorder, substance / medication induced anxiety disorder, anxiety disorder attributed to another medical condition, other specified anxiety disorders, obsessive-compulsive disorder, body dysmorphic disorder, hoarding disorder, trichotillomania (hair pulling disorder), skin picking disorder, substance / medication induced obsessive-compulsive disorder and related disorders, obsessive-compulsive disorder and related disorders attributed to another medical condition, other specified obsessive-compulsive disorder and unspecified related disorders.
[0065] Trauma and stressor-related disorders: reactive attachment disorder, disinhibited social engagement disorder, post-traumatic stress disorder, acute stress disorder, other specified trauma and stressor-related disorders, unspecified trauma and stressor-related disorders, somatic symptom and related disorders: somatic symptom disorder, illness anxiety disorder, conversion disorder (functional neurological symptom disorder), psychological factors affecting other medical conditions, factitious disorders, other specified somatic symptoms and related disorders, unspecified somatic symptoms and related disorders, feeding and eating disorders: pica, rumination disorder, avoidant / restrictive food intake disorder, anorexia nervosa, bulimia, binge eating disorder, other specified feeding or eating disorders, unspecified feeding or eating disorders.
[0066] Sleep-wake disorders: insomnia, hypersomnia, narcolepsy, breathing-related sleep disorder, obstructive sleep apnea, hypopnea, central sleep apnea, sleep-related hypoventilation, circadian rhythm sleep-wake disorder, parasomnia, non-rapid eye movement sleep arousal disorder, sleepwalking, sleep terrors, nightmares, rapid eye movement sleep behavior disorder, restless legs syndrome, substance / medication-induced sleep disorder, other specified insomnia, unspecified insomnia, other specified hypersomnia, unspecified hypersomnia, other specified sleep-wake disorder, unspecified sleep-wake disorder, sexual dysfunction: delayed ejaculation, erectile dysfunction, female orgasm disorder, female sexual interest / arousal disorder, pelvic genital pain / insertion disorder, male sexual desire deficiency disorder, premature ejaculation, substance / medication-induced sexual dysfunction, other specified sexual dysfunction, unspecified sexual dysfunction, gender dysphoria, gender dysphoria, other specified gender dysphoria, unspecified gender dysphoria.
[0067] F50-F59 Behavioral syndromes related to physiological disturbances and physical factors
[0068] F50 Eating disorders; F51 Sleep disorders not attributable to a substance or known physiological condition; F52 Sexual dysfunction not attributable to a substance or known physiological condition; F53 Mental and behavioral disorders related to the puerperium, not classified elsewhere; F54 Psychological and behavioral factors associated with symptoms or diseases classified elsewhere; F55 Abuse of nonpsychoactive substances; F59 Unspecified behavioral syndrome associated with physiological disturbances and physical conditions.
[0069] F60-F69 Adult personality and behavioral disorders
[0070] F60 Specific personality disorders; F63 Impulse disorders; F64 Gender identity disorders; F65 Paraphilias; F66 Other sexual disorders; F68 Other adult personality and behaviour disorders; F69 Unspecified adult personality and behaviour disorders.
[0071] Disruptive, impulse-control, and conduct disorders: oppositional defiant disorder, paroxysmal explosive disorder, conduct disorder, antisocial personality disorder, pyromania, kleptomania, other specified disruptive, impulse-control, and conduct disorders, unspecified disruptive, impulse-control, and conduct disorders.
[0072] Personality disorder, general personality disorder, cluster A personality disorder, delusional personality disorder, schizotypal personality disorder, schizotypal personality disorder, cluster B personality disorder, antisocial personality disorder, borderline personality disorder, histrionic personality disorder, narcissistic personality disorder, cluster C personality disorder, avoidant personality disorder, dependent personality disorder, obsessive-compulsive personality disorder, other personality disorder, personality changes attributed to another medical condition, other specified personality disorder, unspecified personality disorder, further conditions studied, minor psychotic syndrome, depressive episode with short-duration hypomania, persistent complicated mourning disorder, gaming disorder, neurobehavioral disorder associated with prenatal alcohol exposure, suicidal behavior disorder, nonsuicidal self-injury.
[0073] F70-F79 Intellectual disability
[0074] F70 Mild intellectual disability; F71 Moderate intellectual disability; F72 Severe intellectual disability; F73 Profound intellectual disability; F78 Other intellectual disability; F79 Unspecified intellectual disability.
[0075] F80-F89 Pervasive and specific developmental disorders
[0076] F80 Specific speech and language development disorder; F81 Specific learning skill development disorder; F82 Specific motor function development disorder; F84 Pervasive developmental disorder; F88 Other mental development disorder; F89 Unspecified mental development disorder. Neurodevelopmental disorder, Intellectual disability, Intellectual disability (mental developmental disorder), Global developmental delay, Intellectual disability (mental developmental disorder, unspecified), Communication disorder, Language disorder, Speech disorder (formerly known as phonological disorder), Childhood-onset dysphonia (stuttering), Social (pragmatic) communication disorder, Unspecified communication disorder, Autism spectrum disorder, Autism spectrum disorder, Attention deficit / hyperactivity disorder, Attention deficit / hyperactivity disorder, Other specified Attention deficit / hyperactivity disorder, Unspecified Attention deficit / hyperactivity disorder, Specific learning disorder, Specific learning disorder, Movement disorder, Developmental coordination disorder, Stereotyped movement disorder, Tic disorder, Tourette's disorder, Persistent (chronic) motor or vocal tic disorder, Transient tic disorder, Other specified tic disorder, Unspecified tic disorder, Other neurodevelopmental disorder, Other specified neurodevelopmental disorder, Unspecified neurodevelopmental disorder.
[0077] F90-F98 are behavioral and emotional disorders that usually develop during childhood and adolescence.
[0078] F90 Attention deficit hyperactivity disorder; F91 Conduct disorder; F93 Emotional disorders specific to childhood; F94 Social dysfunction specific to childhood and adolescence; F95 Tic disorder; F98 Other behavioral and emotional disorders with onset typically in childhood and adolescence.
[0079] As used herein, neurological disorders, conditions, diseases or disorders include, but are not limited to, the following and all intermediate ICD-10 codes within the definition:
[0080] G00-G09 Inflammatory diseases of the central nervous system
[0081] G00 Bacterial meningitis, not classified elsewhere; G01 Meningitis in bacterial diseases classified elsewhere; G02 Meningitis in other infectious and parasitic diseases classified elsewhere; G03 Meningitis due to other and unspecified causes; G04 Encephalitis, myelitis and encephalomyelitis; G05 Encephalitis, myelitis and encephalomyelitis in diseases classified elsewhere; G06 Intracranial and intraspinal abscesses and granulomas; G07 Intracranial and intraspinal abscesses and granulomas in diseases classified elsewhere; G08 Intracranial and intraspinal phlebitis and thrombophlebitis; G09 Sequelae of inflammatory diseases of the central nervous system. Add exclusions: certain conditions of perinatal origin (P04-P96), certain infectious and parasitic diseases (A00-B99), complications of pregnancy, delivery and the puerperium (O00-O9A), congenital malformations, deformations and chromosomal abnormalities (Q00-Q99), endocrine, nutritional and metabolic diseases (E00-E88), injury, poisoning and certain other consequences of external causes (S00-T88), neoplasms (C00-D49), symptoms, signs and abnormal clinical and laboratory findings, not classified elsewhere (R00-R94).
[0082] G10-G14 Generalized atrophy primarily affecting the central nervous system
[0083] G10 Huntington's disease; G11 Hereditary ataxias; G12 Spinal muscular atrophy and related syndromes; G13 Generalized atrophies primarily affecting the central nervous system in diseases classified elsewhere; G14 Post-polio syndrome.
[0084] G20-G26 Extrapyramidal and movement disorders
[0085] G20 Parkinson's disease; G21 Secondary Parkinson's disease; G23 Other degenerative disorders of the basal ganglia; G24 Insufficient muscle tone; G25 Other extrapyramidal and movement disorders; G26 Extrapyramidal and movement disorders in diseases classified elsewhere.
[0086] G30-G32 Other degenerative diseases of the nervous system
[0087] G30 Alzheimer's disease; G31 Other degenerative diseases of the nervous system, not classified elsewhere; G32 Other degenerative diseases of the nervous system in diseases classified elsewhere.
[0088] G35-G37 Demyelinating diseases of the central nervous system
[0089] G35 Multiple sclerosis; G36 Other acute disseminated demyelination; G37 Other demyelinating diseases of the central nervous system.
[0090] G40-G47 Intermittent and paroxysmal disorders
[0091] G40 Epilepsy and recurrent epileptic seizures; G43 Migraine; G44 Other headache syndromes; G45 Transient ischemic attack and related syndromes; G46 Cerebrovascular syndromes in cerebrovascular diseases; G47 Sleep disorders.
[0092] G50-G59 Nerve, nerve root and plexus disorders
[0093] G50 Trigeminal nerve disorder; G51 Facial nerve disorder; G52 Other cranial nerve disorder; G53 Cranial nerve disorder in diseases classified elsewhere; G54 Nerve root and plexus disorder; G55 Nerve root and plexus compression in diseases classified elsewhere; G56 Upper extremity mononeuropathy; G57 Lower extremity mononeuropathy; G58 Other mononeuropathy; G59 Mononeuropathy in diseases classified elsewhere. Add exclusions: Current traumatic nerve, nerve root and plexus disorder, body region neuralgia NOS (M79.2), neuritis NOS (M79.2), pregnancy peripheral neuritis (O26.82), radiculitis NOS (M54.1).
[0094] G60-G65 Polyneuropathy and other peripheral nervous system disorders
[0095] G60 Hereditary and idiopathic neuropathies; G61 Inflammatory polyneuropathy; G62 Other and unspecified polyneuropathy; G63 Polyneuropathy in diseases classified elsewhere; G64 Other peripheral nervous system disorders; G65 Sequelae of inflammatory and toxic polyneuropathy.
[0096] G70-G73 Myoneural junction and muscle diseases
[0097] G70 Myasthenia gravis and other myoneural disorders; G71 Primary muscle disorders; G72 Other and unspecified myopathies; G73 Disorders of the myoneural junction and muscles in diseases classified elsewhere.
[0098] G80-G83 Cerebral palsy and other paralytic syndromes
[0099] G80 Cerebral palsy; G81 Hemiplegia and hemiparesis; G82 Paraplegia (posterior limb paresis) and quadriplegia (quadriplegia); G83 Other paralytic syndromes.
[0100] G89-G99 Other nervous system disorders
[0101] G89 Pain, not classified elsewhere; G90 Autonomic nervous system disorders; G91 Hydrocephalus; G92 Toxic encephalopathy; G93 Other brain disorders; G94 Other brain disorders in diseases classified elsewhere; G95 Other and unspecified spinal cord disorders; G96 Other central nervous system disorders; G97 Intraoperative and postoperative complications and disorders of the nervous system, not classified elsewhere; G98 Other nervous system disorders not classified elsewhere; G99 Other nervous system disorders in diseases classified elsewhere.
[0102] As used herein, "treatment-resistant depression" (TRD) is a shorthand notation for all related terms, management approaches, and the like, as defined herein, including, but not limited to, non-responder depression, refractory depression, partially responding depression, optimization strategy, switching strategy, combination strategy, augmentation strategy, bupropion, mirtazapine, mianserine, lithium, thyroid hormone, second generation antipsychotics (SGA), dopamine agonists, lamotrigine, psychostimulants, dextromethorphan, dextrorphan, ketamine, omega-3 fatty acids, pindolol, sex steroids, and glucocorticoid agents. Management approaches include treatment strategies such as: (1) switching from an ineffective antidepressant to a new antidepressant from a similar or different class; (2) combining a current antidepressant regimen with a second antidepressant from a different class; and (3) augmenting a current antidepressant regimen with a second agent that is not considered an antidepressant in itself.
[0103] As used herein, the terms "reduce," "decrease," "lessen," and similar terms mean a decrease of at least about 10%, about 15%, about 20%, about 25%, about 35%, about 50%, about 75%, about 80%, about 85%, about 90%, about 95%, about 97%, or more.
[0104] As used herein, the terms "improve," "increase," "enhancet" and similar terms indicate an increase of at least about 10%, about 15%, about 20%, about 25%, about 50%, about 75%, about 100%, about 150%, about 200%, about 300%, about 400%, about 500% or more.
[0105] As used herein, the terms "binds" or "binding" or grammatical equivalents refer to the affinity of compositions for each other. "Specific binding" is where the binding is selective between two molecules. A particular example of specific binding is the binding that occurs between an antibody and an antigen. Generally, specific binding occurs when the dissociation constant (KD) is less than about 1×10 -5 M or less than about 1×10 -6 M or 1×10 -7 When M is used, specific binding can be distinguished from nonspecific binding. Specific binding can be detected, for example, by ELISA, immunoprecipitation, coprecipitation with or without chemical cross-linking, two-hybrid analysis, etc. Appropriate controls can be used to distinguish "specific" binding from "nonspecific" binding.
[0106] In one embodiment, a variety of other therapeutic agents can be used for administration with the compositions and methods provided herein.
[0107] The psychoactive compounds provided herein can be used for various therapeutic purposes. In one embodiment, the compound is administered to a subject to treat neuropsychiatric disorders. For the purposes of the compositions and methods provided herein, "subjects" include humans and other animals, preferably mammals and most preferably humans. Therefore, the compounds provided herein have both human therapy and veterinary applications. In another embodiment, the subject is a mammal, and in yet another embodiment, the subject is a human. "Condition" or "disease" herein means a condition that can be improved by administering a pharmaceutical composition comprising a compound provided herein.
[0108] The methods and compositions described herein can be used to prevent neuropsychiatric diseases, and to improve the signs and / or symptoms of neuropsychiatric diseases. The term "treating" or "treatment" used to refer to the treatment of a neuropsychiatric disease in a subject includes: preventing, inhibiting or improving a neuropsychiatric disease in a subject, and alleviating or improving the signs or symptoms of a neuropsychiatric disease. Treatment goals may include endpoints, such as improvements in the DSM-5 severity scale to measure whether resilience and quality of life are enhanced, as well as the engagement of positive cognitive-emotional systems, and a corresponding reduction in negative emotions.
[0109] It will be understood by those skilled in the art that the methods of treatment and / or prevention comprising administering the psychoactive compounds provided herein to treat and / or prevent one or more indications as described herein also include: the use of the psychoactive compounds provided herein for the manufacture of a medicament for treating and / or preventing one or more indications as described herein; and the use of the psychoactive compounds provided herein for treating and / or preventing one or more indications as described herein.
[0110] In some embodiments, a method for treating and / or preventing a neuropsychiatric disorder and / or improving its symptoms in a subject in need thereof comprises administering to the subject a therapeutically effective dose of a psychoactive compound as provided herein. In some embodiments, a method for treating and / or preventing a neuropsychiatric disorder and / or improving its symptoms in a subject in need thereof comprises administering to the subject a therapeutically effective dose of a psychoactive compound as provided herein in a controlled environment, wherein the subject is provided with psychological support.
[0111] The term "about" or "approximately" means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" may mean within 1 or more standard deviations, as practiced in the art. Alternatively, when reference is made to measurable values such as amounts, durations, concentrations, and the like, variations of ±20% or ±10%, more preferably ±5%, even more preferably ±1% or ±0.5%, and still more preferably ±0.1% of the specified value may be contemplated as being suitable for performing the disclosed methods.
[0112] Pharmaceutical compositions for the psychoactive compounds and methods provided herein are contemplated. Formulations of the compositions and methods provided herein are prepared for storage by mixing the compound having the desired purity with a pharmaceutically acceptable carrier, excipient or stabilizer, as appropriate, in the form of a lyophilized formulation or an aqueous solution. Acceptable carriers, excipients or stabilizers are nontoxic to the recipient at the dosages and concentrations used and include: buffers such as phosphates, citrates, acetates and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl alcohol or benzyl alcohol); alkyl parabens such as methyl paraben or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins such as serum albumin, gelatin or immunoglobulin. globulin; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates, including glucose, mannose or dextrin; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; sweeteners and other flavoring agents; fillers such as microcrystalline cellulose, lactose, corn and other starches; binders; additives; colorants; salt-forming counterions such as sodium ions; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants or polyethylene glycol (PEG). In another embodiment, the pharmaceutical compositions provided herein are in a water-soluble form, such as in the form of a pharmaceutically acceptable salt, which is meant to include both acid addition salts and base addition salts. "Pharmaceutically acceptable acid addition salts" refer to those salts which retain the biological effectiveness of the free bases and which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. "Pharmaceutically acceptable base addition salts" include those derived from inorganic bases, such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, and the like. Particularly preferred are ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines (including naturally occurring substituted amines), cyclic amines and basic ion exchange resins such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine and ethanolamine. The formulation to be used for in vivo administration is preferably sterile. This is easily achieved by filtration through sterile filtration membranes or other methods.
[0113] Pharmaceutically acceptable excipients for formulations of the psychoactive compounds provided herein include, but are not limited to, diluents such as microcrystalline cellulose, starch, mannitol, anhydrous dibasic calcium phosphate or a blend of silicon dioxide, calcium carbonate, microcrystalline cellulose and talc; disintegrants such as sodium starch glycolate or croscarmellose sodium; binders such as povidone, copovidone or hydroxypropyl cellulose; lubricants such as magnesium stearate or sodium stearyl fumarate; glidants such as colloidal silicon dioxide; and film coatings such as Opadry II white or PVA-based brown Opadry II.
[0114] The psychoactive compounds provided herein can also be encapsulated in microcapsules prepared by methods including, but not limited to, coacervation techniques, interfacial polymerization (e.g., using hydroxymethylcellulose or gelatin microcapsules or poly(methyl methacrylate) microcapsules), colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules), and macroemulsions. Sustained release formulations can be prepared. Suitable examples of sustained release formulations include semipermeable matrices of solid hydrophobic polymers in the form of shaped articles, such as films or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels such as poly(2-hydroxyethyl-methacrylate) or poly(vinyl alcohol)), polylactic acid, copolymers of L-glutamic acid and γ-ethyl-L-glutamic acid, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers (which are injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid), which is a microsphere-based delivery system composed of the desired bioactive molecule incorporated into a matrix of poly-DL-lactide-co-glycolide (PLG).
[0115] The administration of the pharmaceutical composition comprising the psychotropic agent provided herein, preferably in the form of a sterile aqueous solution, can be carried out in a variety of ways, including but not limited to oral, subcutaneous, intravenous, intranasal, intraaural, transdermal, topical (e.g., gel, ointment, lotion, cream, etc.), intraperitoneal, intramuscular, intrapulmonary, vaginal, parenteral, rectal or intraocular. As known in the art, the pharmaceutical composition can be formulated accordingly depending on the mode of introduction.
[0116] In some embodiments, the pharmaceutical formulation is an oral dosage form. In some embodiments, the pharmaceutical formulation is a parenteral dosage form. In some embodiments, the pharmaceutical composition comprises a tablet. In some embodiments, the pharmaceutical composition comprises a capsule. In some embodiments, the pharmaceutical composition comprises a dry powder. In some embodiments, the pharmaceutical composition comprises a solution. In some embodiments, more than one dosage form is administered to a subject at substantially the same time. In some embodiments, a subject can be administered the entire therapeutic dose in one tablet or capsule. In some embodiments, the therapeutic dose can be divided into multiple tablets or capsules.
[0117] In some embodiments, the dosage of the psychoactive compound provided herein can be in the range of about 1 mg to about 100 mg. For example, the dosage can be about 1 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg or about 100 mg. In some embodiments, the dosage of the psychoactive compound provided herein is between about 0.1 mg to about 100 mg, about 1 mg to about 50 mg or about 5 mg to about 30 mg. In some embodiments, the dosage of the psychoactive compound provided herein is about 1 mg, about 10 mg or about 25 mg. In some embodiments, the dosage of the psychoactive compound provided herein is in the range of about 0.001 mg to about 1 g. In some embodiments, the dosage of the psychoactive compound provided herein is in the range of about 100 mg to about 250 mg. In some embodiments, the dose of the psychoactive compound provided herein is about 25 mg.
[0118] In some embodiments, the psychoactive compound provided herein is administered daily. In some embodiments, the psychoactive compound is administered twice a day. In some embodiments, the psychoactive compound is administered three times a day. In some embodiments, the psychoactive compound is administered every other day. In some embodiments, the psychoactive compound is administered every three days. In some embodiments, the psychoactive compound is administered every four days. In some embodiments, the psychoactive compound is administered every five days. In some embodiments, the psychoactive compound is administered weekly. In some embodiments, the psychoactive compound is administered every other week. In some embodiments, the psychoactive compound is administered every three weeks. In some embodiments, the psychoactive compound is administered monthly.
[0119] In some embodiments, about 5 mg of the psychoactive compound is administered daily. In some embodiments, about 5 mg of the psychoactive compound is administered twice a day. In some embodiments, about 5 mg of the psychoactive compound is administered three times a day. In some embodiments, about 5 mg of the psychoactive compound is administered every other day. In some embodiments, about 5 mg of the psychoactive compound is administered every three days. In some embodiments, about 5 mg of the psychoactive compound is administered every four days. In some embodiments, about 5 mg of the psychoactive compound is administered every five days. In some embodiments, about 5 mg of the psychoactive compound is administered weekly. In some embodiments, about 5 mg of the psychoactive compound is administered every other week. In some embodiments, about 5 mg of the psychoactive compound is administered every three weeks. In some embodiments, about 5 mg of the psychoactive compound is administered monthly.
[0120] In some embodiments, about 25 mg of the psychoactive compound is administered daily. In some embodiments, about 25 mg of the psychoactive compound is administered twice a day. In some embodiments, about 25 mg of the psychoactive compound is administered three times a day. In some embodiments, about 25 mg of the psychoactive compound is administered every other day. In some embodiments, about 25 mg of the psychoactive compound is administered every three days. In some embodiments, about 25 mg of the psychoactive compound is administered every four days. In some embodiments, about 25 mg of the psychoactive compound is administered every five days. In some embodiments, about 25 mg of the psychoactive compound is administered weekly. In some embodiments, about 25 mg of the psychoactive compound is administered every other week. In some embodiments, about 25 mg of the psychoactive compound is administered every three weeks. In some embodiments, about 25 mg of the psychoactive compound is administered monthly.
[0121] In some embodiments, about 50 mg of the psychoactive compound is administered daily. In some embodiments, about 50 mg of the psychoactive compound is administered twice a day. In some embodiments, about 50 mg of the psychoactive compound is administered three times a day. In some embodiments, about 50 mg of the psychoactive compound is administered every other day. In some embodiments, about 50 mg of the psychoactive compound is administered every three days. In some embodiments, about 50 mg of the psychoactive compound is administered every four days. In some embodiments, about 50 mg of the psychoactive compound is administered every five days. In some embodiments, about 50 mg of the psychoactive compound is administered weekly. In some embodiments, about 50 mg of the psychoactive compound is administered every other week. In some embodiments, about 50 mg of the psychoactive compound is administered every three weeks. In some embodiments, about 50 mg of the psychoactive compound is administered monthly.
[0122] In some embodiments, about 100 mg of the psychoactive compound is administered daily. In some embodiments, about 100 mg of the psychoactive compound is administered twice a day. In some embodiments, about 100 mg of the psychoactive compound is administered three times a day. In some embodiments, about 100 mg of the psychoactive compound is administered every other day. In some embodiments, about 100 mg of the psychoactive compound is administered every three days. In some embodiments, about 100 mg of the psychoactive compound is administered every four days. In some embodiments, about 100 mg of the psychoactive compound is administered every five days. In some embodiments, about 100 mg of the psychoactive compound is administered weekly. In some embodiments, about 100 mg of the psychoactive compound is administered every other week. In some embodiments, about 100 mg of the psychoactive compound is administered every three weeks. In some embodiments, about 100 mg of the psychoactive compound is administered monthly.
[0123] In some embodiments, about 150 mg of the psychoactive compound is administered daily. In some embodiments, about 150 mg of the psychoactive compound is administered twice a day. In some embodiments, about 150 mg of the psychoactive compound is administered three times a day. In some embodiments, about 150 mg of the psychoactive compound is administered every other day. In some embodiments, about 150 mg of the psychoactive compound is administered every three days. In some embodiments, about 150 mg of the psychoactive compound is administered every four days. In some embodiments, about 150 mg of the psychoactive compound is administered every five days. In some embodiments, about 150 mg of the psychoactive compound is administered weekly. In some embodiments, about 150 mg of the psychoactive compound is administered every other week. In some embodiments, about 150 mg of the psychoactive compound is administered every three weeks. In some embodiments, about 150 mg of the psychoactive compound is administered monthly.
[0124] In some embodiments, about 200 mg of the psychoactive compound is administered daily. In some embodiments, about 200 mg of the psychoactive compound is administered twice a day. In some embodiments, about 200 mg of the psychoactive compound is administered three times a day. In some embodiments, about 200 mg of the psychoactive compound is administered every other day. In some embodiments, about 200 mg of the psychoactive compound is administered every three days. In some embodiments, about 200 mg of the psychoactive compound is administered every four days. In some embodiments, about 200 mg of the psychoactive compound is administered every five days. In some embodiments, about 200 mg of the psychoactive compound is administered weekly. In some embodiments, about 200 mg of the psychoactive compound is administered every other week. In some embodiments, about 200 mg of the psychoactive compound is administered every three weeks. In some embodiments, about 200 mg of the psychoactive compound is administered monthly.
[0125] In some embodiments, about 250 mg of the psychoactive compound is administered daily. In some embodiments, about 250 mg of the psychoactive compound is administered twice a day. In some embodiments, about 250 mg of the psychoactive compound is administered three times a day. In some embodiments, about 250 mg of the psychoactive compound is administered every other day. In some embodiments, about 250 mg of the psychoactive compound is administered every three days. In some embodiments, about 250 mg of the psychoactive compound is administered every four days. In some embodiments, about 250 mg of the psychoactive compound is administered every five days. In some embodiments, about 250 mg of the psychoactive compound is administered every day. In some embodiments, about 250 mg of the psychoactive compound is administered weekly. In some embodiments, about 250 mg of the psychoactive compound is administered every other week. In some embodiments, about 250 mg of the psychoactive compound is administered every three weeks. In some embodiments, about 250 mg of the psychoactive compound is administered monthly.
[0126] In some embodiments, an initial dose of a psychoactive compound as provided herein is administered, which is subsequently reinforced by administering a second dose of a psychoactive compound 30 minutes to 4 hours later. In some embodiments, the booster dose is administered about 30 minutes after the initial dose. In some embodiments, the booster dose is administered about 60 minutes after the initial dose. In some embodiments, the booster dose is administered about 90 minutes after the initial dose. In some embodiments, the booster dose is administered about 120 minutes after the initial dose. In some embodiments, the booster dose is administered about 150 minutes after the initial dose. In some embodiments, the booster dose is administered about 180 minutes after the initial dose. In some embodiments, the booster dose is administered about 210 minutes after the initial dose. In some embodiments, the booster dose is administered about 240 minutes after the initial dose.
[0127] In some embodiments, the booster dose is 10% to 100% of the amount of the initial dose. In some embodiments, the booster dose is the same amount as the initial dose. In some embodiments, the booster dose is about half the amount of the initial dose. In some embodiments, this dosing schedule is performed daily. In some embodiments, this dosing schedule is performed twice a day. In some embodiments, this dosing schedule is performed three times a day. In some embodiments, this dosing schedule is performed every other day. In some embodiments, this dosing schedule is performed every three days. In some embodiments, this dosing schedule is performed every four days. In some embodiments, this dosing schedule is performed every five days. In some embodiments, this dosing schedule is performed weekly. In some embodiments, this dosing schedule is performed every other week. In some embodiments, this dosing schedule is performed every three weeks. In some embodiments, this dosing schedule is performed monthly.
[0128] In some embodiments, the dosage of the psychoactive compound provided herein can be within the range of about 1 mg / kg to about 100 mg / kg. For example, the dosage can be about 1 mg / kg, about 5 mg / kg, about 10 mg / kg, about 15 mg / kg, about 20 mg / kg, about 25 mg / kg, about 30 mg / kg, about 35 mg / kg, about 40 mg / kg, about 45 mg / kg, about 50 mg / kg, about 55 mg / kg, about 60 mg / kg, about 65 mg / kg, about 70 mg / kg, about 75 mg / kg, about 80 mg / kg, about 85 mg / kg, about 90 mg / kg, about 95 mg / kg or about 100 mg / kg. In some embodiments, the dosage of the psychoactive compound provided herein is between about 0.1 mg / kg to about 100 mg / kg, about 1 mg / kg to about 50 mg / kg or about 5 mg / kg to about 30 mg / kg. In some embodiments, the dosage of the psychoactive compound provided herein is about 1 mg / kg, about 10 mg / kg, or about 25 mg / kg. In some embodiments, the dosage of the psychoactive compound provided herein is in the range of about 0.001 mg / kg to about 1 g / kg. In some embodiments, the dosage of the psychoactive compound provided herein is in the range of about 100 mg / kg to about 250 mg / kg. In some embodiments, the dosage of the psychoactive compound provided herein is about 25 mg / kg.
[0129] In some embodiments, the psychoactive compounds provided herein are administered, for example, in a single dose or one or more times per week (up to twice a day or even three times a day). In some embodiments, the psychoactive compounds provided herein are administered according to the dosing schedule provided herein. In some embodiments, the psychoactive compounds provided herein are administered in the form of extended release or sustained release formulations, for example to achieve the dosing regimen disclosed herein, and 50 mg to 1 g are released to those patients according to a set schedule based on the indications being treated in the patients.
[0130] In one embodiment, the term "subject" refers to a mammal (including a human) that is in need of therapy for a condition or its sequelae or is susceptible to a condition or its sequelae. Subjects may include dogs, cats, pigs, cows, sheep, goats, horses, rats and mice, and humans. The term "subject" does not exclude individuals that are normal in all respects.
[0131] In some embodiments, the subject is male. In some embodiments, the subject is female. In some embodiments, the female subject is pregnant or postpartum. The subject may be an elderly subject, a child subject, a teenager subject, a young adult subject, or a middle-aged subject. In some embodiments, the subject is less than about 18 years old. In some embodiments, the subject is at least about 18 years old. In some embodiments, the subject is about 5-10, about 10-15, about 15-20, about 20-25, about 25-30, about 30-35, about 35-40, about 40-45, about 45-50, about 50-55, about 55-60, about 60-65, about 65-70, about 70-75, about 75-80, about 85-90, about 90-95, or about 95-100 years old.
[0132] As used herein, the singular forms "a", "an" and "the" include plural references unless the context clearly indicates otherwise. For example, the term "a molecule" may also include plural molecules.
[0133] Unless the context clearly indicates otherwise, reference to a specific value includes at least that specific value. When a range of values is expressed, another embodiment includes from one specific value and / or to another specific value. In addition, the values stated in the reference range include every value within the range. All ranges are inclusive and combinable.
[0134] As used herein, the phrase "and / or" should be understood to mean "either or both" of the elements so combined, i.e., elements that are present jointly in some cases and not jointly in other cases. Multiple elements listed using "and / or" should be interpreted in the same manner, i.e., "one or more" elements so combined. Other elements may be present in addition to the elements specifically identified by the "and / or" clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, reference to "A and / or B", when used in conjunction with an open-ended phrase such as "comprising", in one embodiment, may refer to only A (optionally including elements other than B); in another embodiment, may refer to only B (including elements other than A); in another embodiment, may refer to both A and B (including other elements); and so on.
[0135] As used herein, "or" should be understood to have the same meaning as "and / or" defined above. For example, when separating each item in a list, "or" or "and / or" should be interpreted as inclusive, that is, not only including at least one of multiple elements or lists of elements, but also including more than one, and other unlisted items that exist as appropriate. Only terms indicating diametrically opposite, such as "only one of ... " or "exactly one of ... " or "consisting of ... " when used in an embodiment will refer to including exactly one element in multiple elements or lists of elements. In general, when placed before exclusive terms such as "any", "one of ... ", "only one of ... " or "exactly one of ... ", the term "or" as used herein should only be interpreted as indicating exclusive alternatives (i.e. "one or the other but not both").
[0136] As used herein, the phrase "at least one" when referring to a list of one or more elements should be understood to mean at least one element selected from any one or more elements in the list of elements, but does not necessarily include at least one of each element specifically listed in the list of elements and does not exclude any combination of elements in the list of elements. This definition also allows for the presence of elements other than the elements specifically identified in the list of elements to which the phrase "at least one" refers, whether related or unrelated to those specifically identified elements. Thus, as a non-limiting example, "at least one of A and B" (or equivalently "at least one of A or B" or equivalently "at least one of A and / or B") may refer to at least one (including more than one) A without B (and including elements other than B) in one embodiment; at least one (including more than one) B without A (and including elements other than A) in another embodiment; at least one (including more than one) A and at least one (including more than one) B (and including other elements) in yet another embodiment; and so on.
[0137] It is specifically intended that the various features described herein can be used in any combination, unless the context dictates otherwise.
[0138] Any patent, patent application publication, or scientific publication cited herein is hereby incorporated by reference in its entirety.
[0139] The following examples are presented in order to more fully illustrate the preferred embodiments of the present invention. However, they should in no way be construed as limiting the broad scope of the present invention.
[0140] Examples
[0141] Example 1: Effects of methylketone, 2C-B and MBDB on fear extinction plasticity and dendritic architecture in mice
[0142] The key question in experimental studies is how the short half-life of the compound translates into long-term behavioral changes. One plausible mechanism is neuroplasticity. In fact, the administration of psychoactive compounds can drive persistent modifications in the neural architecture of the brain by strengthening synaptic connections or increasing the number of synaptic connections. However, current evidence supporting this view comes mainly from studies on cultured neurons. It is still unknown to what extent neuroplasticity is induced by psychoactive compounds in the mammalian brain, and whether synaptic remodeling occurs in brain areas implicated in neuropsychiatric disorders.
[0143] In this study, the effects of various psychoactive drugs were compared in an in vivo rodent model. A variety of conditions were tested, including 3 psychoactive compounds of interest (methyl ketone, 2C-B, and MBDB) in two groups (e.g., imipramine or other antidepressants / anxiolytics), positive controls (e.g., another antidepressant / anxiolytic), and vehicle controls (saline). The dose-response curves of the psychoactive compounds were characterized by measuring the head twitch response of the mice. The plasticity-enhancing effect of each compound on fear extinction behavior after a single dose was also determined. Subsequently, 2-photon imaging microscopy was used to determine the longitudinal effects of each compound on the density and turnover of dendritic spines after a single dose (Shao LX et al. Neuron. June 25, 2021: S0896-6273(21)00423-2. doi: 10.1016 / j.neuron.2021.06.008.).
[0144] Determination of dose-response curves in C57BL / 6J mice
[0145] It is important to determine the dose range associated with mouse behavior. In order to construct a dose-response curve, a series of doses of 3 psychoactive compounds (methyl ketone, 2C-B, MBDB) were quantitatively measured in adult 6-8 week-old C57BL / 6J mice, with 40 mice tested per condition. In brief, animals were placed in an arena in a soundproof cubicle. The arena was illuminated by near-infrared lighting. The movement of mice in all arenas was captured simultaneously by a high-speed camera installed on the top. Each animal received an intraperitoneal injection of 1 of 5 doses of a compound, with a dose range selected based on the literature. Mice were randomly assigned to the group. Videos were recorded for about 10 minutes after administration. In the subset studied, videos were recorded for up to 2 hours to draw a time course. For analysis, head twitches were counted by an experimenter who was unaware of the experimental conditions. These experiments are used to report the dose to be used for further research.
[0146] Determining the effects of methylone, MBDB, and 2C-B on fear extinction plasticity
[0147] Neuroplasticity can promote the change of emotional learning. Fear elimination is a behavior, wherein repeated exposure to relevant fear learning stimuli can reduce the intensity of fear response, and it can be related to the mechanism of action of these compounds in reducing anxiety or fear. It is unknown to what extent novel phenylethylamine can enhance fear elimination. Here, in adult mice, the fear elimination rate is determined after the drug is administered under 4 conditions (saline, methyl ketone, 2C-B, MBDB), wherein 10 mice are tested for each condition. In brief, each mouse receives tone-electric shock pairing (the 1st day), then on the subsequent day, it receives a single administration of the compound (with the dosage informed by the previous study), and is exposed to fear-related stimuli again after 30 minutes (the 2nd day). On the 3rd day, fear elimination learning is tested by exposing mice to the relevant tones in the fear conditioning (fear conditioning) device again. Fear elimination serves as a model for improving anxiety and fear-related behavior in mental illness, and can be used to identify behavioral effects that can be separated from psychedelic effects. The circuit mechanism of potential plasticity enhancement is subsequently solved in a two-photon imaging experiment.
[0148] Determining long-term effects on dendritic remodeling
[0149] Although psychoactive compounds have been shown to promote neuroplasticity, these experiments investigate how different compounds induce different degrees of structural remodeling. Here, dendritic spine turnover in the medial frontal cortex is determined for 5 conditions (saline, ketamine, methyl ketone, 2C-B, MBDB) in adult mice, with 5 mice tested for each condition. In brief, Thy1-GFP-M transgenic mice are used because a sparse subset of cortical pyramidal neurons express enhanced green fluorescent protein, thereby allowing visualization of their dendritic architecture. Each mouse receives a single administration of the compound (at the dose determined above; for ketamine, 10 mg / kg). Using a two-photon microscope, dendritic spines in remote apical cluster branches are imaged, and dendritic spines are tracked at 7 stages of -3, -1, 1, 3, 5, 7, and about 30 days from the day of administration. Longitudinal imaging of the spines of the same group makes it possible to determine the number density of dendritic spines, as well as turnover kinetics, including spine formation and elimination rates, and the fraction of newly formed spines that indicate new functional synaptic maturation and remain persistent. These results provide data on a variety of psychoactive compounds to demonstrate their suitability for treating neuropsychiatric disorders.
[0150] Example 2: Zebrafish Models of Neuropsychiatric Diseases
[0151] Zebrafish is ideal for developing effective experimental models for major depression, anxiety and pain disorders to discover novel therapeutic agents due to its physiological (neuroanatomy, neuroendocrine, neurochemistry) and genetic homology with mammals, robust phenotypes, and value in high-throughput genetic and chemical genetic screening. Behavioral testing methods (such as avoidance, cognitive and social paradigms) are available in zebrafish and are suitable for identifying depressive-like indices in zebrafish in response to physiological, genetic, environmental and / or psychopharmacological changes. In addition, the high sensitivity of zebrafish to commonly prescribed psychoactive drugs supports the use of this model as a tool for pharmacological research and drug screening. Both adult and larval zebrafish have well-characterized genomes and are widely used for in vivo screening of various psychoactive drugs.
[0152] Reserpine-induced depression model in zebrafish
[0153] As a specific inhibitor of monoamine transporters, serpentine is known to deplete monoamine neurotransmitters (confirmed by liquid chromatography mass spectrometry analysis) and cause a decrease in swimming distance and average speed (hypoactivity) as well as reduced responses to visual and sound stimuli. Serpentine induces depressive-like behaviors in both adult zebrafish and larvae; this serves as an analysis of drugs that affect these despair-like states, such as methylone, 2C-B, and MBDB. A camera algorithm, the Histogram of Oriented Gradient (HOG), analyzes the depressive and hypoactive behaviors of zebrafish shoaling to a precision that is impossible for human observers.
[0154] Zebrafish anxiety model
[0155] Many behaviors including anxiety, fear and stimulus-dependent learning can be assessed as early as the free-swimming larval stage, while social behaviors such as schooling and directed aggression emerge with age. Several anxiety tests are performed sequentially or in combination, including the elevated plus maze, novel tank, light-dark box, and open space test. Known anxiolytic drugs (such as benzodiazepines) are used as positive controls to assess the effects of the drugs on diving and exploratory behavior, tactile aversion, highly active swimming, immobility, erratic swimming, or avoidance of bright areas (scotopic aversion) by adults and avoidance of dark areas by juveniles.
[0156] Example 3: Rodent Models of Neuropsychiatric Disorders
[0157] This example presents rodent models of several neurological and psychiatric conditions used to demonstrate the efficacy of the psychoactive compounds described herein.Primate and rodent models are traditionally used to study the cellular mechanisms and neural circuits of psychedelic drug action.
[0158] Depression: Forced Swim Test (FST)
[0159] The forced swim test (FST) is a classic and most commonly used preclinical behavioral assay for screening compounds with antidepressant-like activity, and has high predictive and face validity (Porsolt et al. (1977) Nature 266:730; Borsini and Meli (1988) Psychopharmacology 94:147). The premise of the FST is that when a rat is placed in a cylinder filled with water, it will initially attempt to escape, but will become immobile over time. This increased immobility reflects behavioral despair, thereby modeling a depressive-like state. A wide range of antidepressant treatments have been shown to consistently shorten immobility time, with observed increases in swimming or climbing associated with serotonin-activating or norepinephrine-activating activity, respectively (Detke et al. (1995) Psychopharmacology 121:66).
[0160] Anxiety: Open Space Test (time spent in the center versus the periphery)
[0161] This behavioral assay is also widely used as an anxiety paradigm, which exploits rodents' innate fear of illuminated open spaces, which are assumed to induce fear or anxiety. Rodents spend more time clinging to the walls of the open space during testing, and these effects are associated with underlying brain areas and mechanisms.
[0162] Methods: Video tracking measuring consecutive beam breaks and / or time spent in the center of an open space versus the periphery. Parameters such as distance traveled and ambulatory activity (horizontal and vertical) over the duration of the test session were also measured.
[0163] Results: Anxiolytics (such as diazepam) increase time spent in the center of an open space (and / or distance traveled) independent of changes in locomotion, which served as positive controls to assess the effects of the agents on these parameters.
[0164] Anxiety: Elevated plus maze
[0165] This behavioral assay is widely used as an anxiety paradigm and is based on the unconditioned responses of rodents to a potentially dangerous environment: maze height, luminosity, and open space are assumed to induce fear or anxiety and are associated with underlying brain areas and mechanisms.
[0166] Methods: Video tracking of time spent in the open arms of the maze relative to the closed arms began at the junction and lasted for 5 minutes. Other behavioral parameters included standing, reaching, and reaching postures.
[0167] Results: Anxiolytics (such as diazepam) increase time spent in open arm activity (duration and / or entries) without decreasing locomotion and were used as positive controls to assess the effects of the agents on these parameters.
[0168] Modified Geller-Seifter collision test
[0169] Rats are trained to press a lever to obtain food under a multiple variable interval fixed ratio (food; food + shock) reinforcement schedule. This task generally exhibits good predictive validity for anxiolytic-like compounds (such as diazepam), which increase punished responses (i.e., antagonize response inhibition during punishment). It also exhibits selectivity for anxiolytics, with apparent no effects in other classes, and the anxiolytic effects of MBDB can be assessed with positive controls such as bupropion.
[0170] Fibromyalgia: Serpentine-induced myalgia model
[0171] Serpentine (1 mg / kg / sc) was administered for 3 days to simulate chronic widespread pain and complex symptoms.
[0172] Methods: Duloxetine (30 mg / kg, po) was administered 60 min before the forced swim test (FST), and rats were subsequently exposed to LDI: a single dose of gamma radiation (0.5 Gy) 1 day before the FST.
[0173] Results: Serpentine significantly increased immobility time in the FST and decreased the amounts of 5-hydroxytryptamine, dopamine, and norepinephrine in the cerebral cortex. It also increased malondialdehyde and nitric oxide levels and decreased glutathione levels in brain tissue. LDI alone or in combination with duloxetine completely antagonized Serpentine-induced fibromyalgia as assessed by measured parameters.
[0174] Fibromyalgia: The Acid-Saline Model
[0175] Allodynia, hyperalgesia and other related fibromyalgia-like symptomatology are rapidly induced via acid injection (pH 4.0). Once induced, animals show hypersensitivity to mechanical and visceral stimuli. Symptoms persist for a minimum of 14 days after induction, allowing for evaluation over time and comparison with vehicle and positive controls (e.g., buprenorphine).
[0176] Example 4: Methylketone case series
[0177] This example is based on a case series of 32 narratives of clinical psychologists administering methylone orally in single or multiple dosing sessions in an outpatient treatment setting. The case series consisted of two data sets (Set 1 and Set 2):
[0178] ● Group 1 : Four case narratives in a healthy population providing information on the safety and tolerability of methylone administered in a single dosing period.
[0179] ● Group 2 : 28 case narratives that provide efficacy and safety information from consecutive patients with a diagnosis of interest (PTSD or MDD) with a baseline assessment. Post-dose efficacy in Group 2 was assessed using Clinical Global Impression-severity (CGI-S) and Clinical Global Impression-improvement (CGI-I) at baseline (described in more detail below) compared to the baseline CGI-S established before the first methylone dose. The CGI-S scale was also assessed in a subset of patients from Group 2 after treatment. Any observed or reported safety events in Group 2 were assessed after the single-dose phase.
[0180] Clinical Global Improvement Scale
[0181] The Clinical Global Assessment (CGI) scale consists of 2 components: CGI-S (“severity”) and CGI-I (“improvement”).
[0182] CGI-S Guidelines
[0183] 1 = Normal - No disease at all, no symptoms of disease in the past seven days
[0184] 2 = Borderline Psychosis - Mild or suspected pathology
[0185] 3 = Mild illness - well-defined symptoms with minimal, if any, distress or difficulty in social and occupational functioning
[0186] 4 = Moderate disease - symptoms causing significant but moderate functional impairment or distress; symptom level may require drug treatment
[0187] 5 = Significant Disorder - Intrusive symptoms that significantly impair social / occupational functioning or cause distress at an intrusive level
[0188] 6 = Severe illness - disruptive pathology, behavior and functioning frequently affected by symptoms, may require help from others
[0189] 7 = In patients with the most severe disease - pathology significantly interferes with many life functions; hospitalization possible
[0190] CGI-I Guidelines
[0191] 1 = Very Improved - Almost completely better; good level of function; minimal symptoms; represents a very substantial change 2 = Much Improved - Much better, with a significant decrease in symptoms; improved level of function, but some symptoms remain
[0192] 3 = Minimally Improved - Slightly better, with little or no clinically meaningful reduction in symptoms. Represents minimal change in basic clinical status, level of care, or functional ability
[0193] 4 = No change - symptoms remain essentially the same
[0194] 5 = Minimally worse - Slight worsening, but probably clinically insignificant; may represent minimal change in basic clinical status or functional ability
[0195] 6 = Great deterioration - clinically significant increase in symptoms and decrease in function
[0196] 7 = Greatly worsened - severe worsening of symptoms and loss of function
[0197] result
[0198] Baseline Demographics: The demographics of Groups 1 and 2 are presented in Table 1.
[0199] Table 1: Baseline demographics
[0200]
[0201] Abbreviations: CGI-S = Clinical Global Assessment-Severity; IQR = interquartile range; Max = maximum; MDD = major depressive disorder; Min = minimum; PTSD = posttraumatic stress disorder
[0202] Group 1 consisted of 4 healthy adult subjects (3 males and 1 female) ranging in age from 28 to 60 years old who were administered methylone in a group setting (3 subjects) or individually (1 subject) as a single administration. Group 1 tended to have a higher proportion of younger male subjects and all were Caucasian. Prior methylone experience was unknown in two subjects and confirmed in the other two subjects (one male and one female).
[0203] Group 2 consisted of 28 patients with PTSD or MDD treated in an outpatient setting. It should be noted that one patient included in the MDD population had a primary diagnosis of bipolar disorder type 1. Overall, males and females were well represented within Group 2 and exhibited similar proportions within the PTSD and MDD subsets.
[0204] The age group aged 18 to <65 years was more than 85% in the overall data set and in the PTSD and MDD subsets, with smaller subsets of elderly patients (≥65 years) in the overall data set and in the PTSD and MDD subsets. The overall age range of Group 2 was wide ranging from 22 to 78 years (mean 45.9 years), with similar distribution in the PTSD and MDD subsets.
[0205] Baseline disease characteristics of group 2
[0206] Main diagnosis
[0207] Overall, the majority of patients included in Group 2 [20 of 28 patients, (71%)] had a primary diagnosis of PTSD, and 29% had a primary diagnosis of MDD or bipolar disorder (7 MDD; 1 bipolar disorder). However, 10 of the 20 patients with PTSD (50%) also had a secondary diagnosis of MDD or depression (6 MDD; 4 depression), with an overall 64.2% having a primary or secondary diagnosis of MDD or depression.
[0208] Prior / concomitant therapy
[0209] For the PTSD subset of Group 2, the most common prior / concomitant therapies reported by 2 or more patients were, in descending order, SSRI (14 patients), talk therapy (7 patients), breath work (4 patients), cognitive and behavioral therapy, and unspecified antidepressants (4 patients each). Most patients had discontinued their respective therapies prior to the initial methylone dosing phase. Within the PTSD subset, 5 patients were on concomitant therapy with SSRIs or other antidepressant classes, and 4 of these patients had an improvement in CGI 1 or 2. The treatment regimen was as follows:
[0210] Fluoxetine 20 to 40 mg
[0211] Fluoxetine (dose not specified)
[0212] Fluoxetine and bupropion (dose not specified)
[0213] Escitalopram (dose not specified)
[0214] Bupropion (dose not specified)
[0215] o Lamotrigine (dose unspecified) was discontinued after the first of 6 periods.
[0216] o The patient had a quasi-psychedelic experience, but it was not specified at which stage this occurred, as described in more detail below.
[0217] For the MDD subset of Group 2, the most common previous / current therapies reported by 2 or more patients were, in descending order, SSRIs (3 patients), talk therapy (3 patients each), psychotherapy (2 patients), and anti-epileptics (2 patients). Most patients had discontinued their respective therapies prior to the initial methylone administration phase. Only a single patient was on concomitant therapy with unspecified doses of escitalopram, clonazepam, lamotrigine, and propranolol at the time of methylone administration, which was tapered after the fifth of the 10 methylone phases. The improvement measure was CGI-I 2 and no safety events were reported.
[0218] Baseline disease severity
[0219] The baseline disease severity (CGI-S) of group 2 is shown in Table 2 and Figure 2 Baseline CGI-S ranged from 4 to 7 and 85.7% of patients had a baseline CGI-S 5 or 6, with similar proportions in both the PTSD and MDD subsets.
[0220] Table 2 Baseline disease severity in group 2 according to CGI-S
[0221]
[0222] Abbreviations: CGI-S = Clinical Global Assessment-Severity; MDD = major depressive disorder; PTSD = posttraumatic stress disorder
[0223] *Included in category "6" was one patient with baseline CGI-S "6+" and in category 7 was one patient with baseline CGI-S "6 or 7"
[0224] Baseline Symptom Checklist
[0225] Figure 1 A baseline symptom checklist is presented that includes symptoms occurring in 2 or more of the 28 patients in Group 2. The most common symptoms included insomnia (12 patients), anhedonia (10 patients), anger (9 patients), and nightmares / night terrors (7 patients).
[0226] Methylone Dosage and Regimen
[0227] Group 1
[0228] The 3 males in Group 1 were dosed in a group setting during a single period with a total methylone dose of 790 mg, administered as a regimen of methylone 280 mg followed by booster doses of 190 mg, 190 mg, and 130 mg. For one female healthy volunteer, the total dose was 870 mg, administered as methylone 250 mg followed by booster doses of 220 mg, 200 mg, and 200 mg.
[0229] Group 2
[0230] Only the period that included methylone administration was considered the administration period. It was noted that some patients continued group therapy with methylone outside of the labeled period, but the improvement in CGI-I from baseline was assessed after the methylone administration period.
[0231] In two cases, one as an initial phase and one as a second phase, MDMA was administered as a single agent. In one case of repeated methylone administration phases, the initial phase consisted of 3 grams of mushrooms administered 30 minutes after methylone administration.
[0232] A single phase occurred in 8 of the 28 cases, with no booster in two of these cases. In the remaining cases, multiple phases occurred, and booster doses were used in all or some of the remaining patients (26 case reports), with multiple booster doses used in some or all phases in 15 patients. The minimum range of the total dose of methylone in each phase was 100 mg to 690 mg and the maximum range was 180 mg to 1020 mg. The maximum total dose in each phase exceeded 500 mg [methylone dose plus booster dose] in only four phases in 3 patients. The methylone dose range was 100 to 270 mg, and the total cumulative dose range of booster doses was 50 mg to 880 mg, but only exceeded 370 mg in two phases in two patients. The minimum range of individual methylone booster doses was 50 mg to 240 mg and the maximum range was 80 mg to 250 mg.
[0233] Security
[0234] Group 1
[0235] No adverse or residual effects were observed or reported for all 4 subjects in Group 1. It was noted that all 3 men were able to walk, make tea, and had no signs of intoxication.
[0236] Group 2
[0237] In the majority of cases included in Group 2 (25 of 28 cases; 89.3%), methylone administration was well tolerated and no safety events were reported. One case report included an adverse event of increased anxiety following administration of 117 mg MDMA in the first period that did not include methylone, and this event occurred before any methylone administration in the subsequent period and did not recur with methylone administration at a total dose of 130 mg (80 mg + 50 mg booster). In 3 patients (all ≥ 65 years old), adverse events were reported following methylone administration as follows:
[0238] I. Case Report A:
[0239] A 75 year old male with a primary diagnosis of PTSD and a history of atrial fibrillation and a pacemaker developed lightheadedness while wearing off medication during Phase 5 of methylone 150 mg and 150 mg booster (highest dose administered). This event was not considered serious and did not require intervention. Previous total dose range was 100-250 mg. There was a negative rechallenge (i.e., repeated methylone administration) with unknown doses administered at home.
[0240] II. Case Report B:
[0241] A 70-year-old male with a primary diagnosis of PTSD and a secondary diagnosis of depression was administered methylone 690 mg during a single session (200 mg followed by booster doses of 250 mg and 240 mg) and did not experience any adverse events during the session, but reported adverse events of insomnia and loss of appetite after the session, which were thought to be due to the mimetic effects of methylone.
[0242] III. Case Report C:
[0243] A 78-year-old male with a primary diagnosis of PTSD and a secondary diagnosis of anxiety, with a history of "well-regulated cardiovascular problems," took methylone over 5 sessions with total doses ranging from 100 to 300 mg per session (100-150 mg methylone and 0 to 150 mg of a booster) and reported a quasi-psychedelic experience, but did not provide dose or other details. No intervention was required.
[0244] effect
[0245] Since Group 1 consisted of healthy volunteers, efficacy is reported for Group 2, which consisted of patients with PTSD and MDD.
[0246] Improvement value
[0247] CGI-I and time to initial improvement
[0248] After treatment with methylone, all patients achieved at least minimal improvement (CGI-3 or better). The highest observed improvement values for the 28 cases included in Group 2 are shown in Table 3 and Figure 3. CGI-I 1 or 2, corresponding to "much improved" or "very much improved" compared to baseline CGI-S, was achieved in 86% of the patients [16 / 20 patients (80%) of the PTSD subset and 8 / 8 patients (100%) of the MDD subset]. In addition, in almost 90% of the patients (25 of 28 patients), initial improvement was observed in the first methylone phase. Two other cases experienced initial improvement after the 2nd and 3rd phases, respectively, and one case required more than a dozen phases to achieve initial improvement.
[0249] Table 3: Improvement values
[0250]
[0251]
[0252] Abbreviation: CGI-I = Clinical Global Assessment-Improvement
[0253] *One case was rated CGI-I "1 / 2" and included in category "1"
[0254] Responsiveness
[0255] Within the PTSD subset of Group 2, 16 case narratives included information on persistence. One case reported no persistent effect, and 15 case narratives reported a persistent effect (lasting 6 months or longer in 12 of these cases, limited to 3 months in one case, and unknown in 2 cases). In one of the cases with an unknown length of persistent response, the narrative stated "subject no longer met illness criteria after the 4th methylone dosing period."
[0256] Within the MDD subset of Group 2, 6 of 8 case narratives included information on persistence. One case reported no persistent effect, and the remaining 5 cases reported a persistent effect that was noted to be 2 years in 2 patients, 5 years in 1 patient, and unknown in 2 patients, but reported as "stable after 13 sessions" in 1 patient and "persistent" in another patient.
[0257] Changes in CGI-S
[0258] Post-treatment CGI-S was reported in only 5 cases, as shown in Table 4, including one patient who was noted to have achieved a stable CGI-S1. One case was noted to have achieved CGI-S1 at times. In the other 5 case narratives that did not include a post-treatment CGI-S score, it was reported that the patient no longer met the diagnostic criteria after treatment and 5 of these cases achieved CGI-I 1.
[0259] Table 4: Maximum Post-treatment CGI-S Change
[0260]
[0261] in conclusion
[0262] Overall, methylone was well tolerated when administered as a single dose and / or booster doses in a single or multiple sessions. No safety events were reported in healthy volunteers or adult patients aged 18 years or < 65 years. Transient safety events were reported in 3 elderly patients, which occurred at high doses and did not recur on re-administration. One of these events included a quasi-psychedelic experience, which occurred in approximately 5-6 of every 2,000 methylone administrations.
[0263] The majority of patients in the PTSD subset (90%) and the majority of patients in the MDD subset (88%) had a baseline CGI-S of 5 or greater ("marked" or "severe" illness), with 2 PTSD patients in the most severe category (i.e., among the "most ill patients") at CGI-S 7. Nevertheless, Group 2 had an improvement magnitude of 1 or 2 in 86% of the total patients [16 / 20 patients in the PTSD subset (80%) and 8 / 8 patients in the MDD subset (100%)], corresponding to "much improved" or "very much improved" compared to baseline CGI-S.
[0264] Example 5: Clinical Evidence for the Use of Methylone for the Treatment of PTSD: A Case Series with Long-term Follow-up PTSD is a debilitating and often chronic psychiatric disorder characterized by a constellation of symptoms, including intrusive memories, distressing dreams, dissociative reactions, physiological reactivity to and avoidance of trauma-related stimuli, negative cognitions and emotions, fatigue, increased arousal, impaired sleep, cognitive dysfunction, irritability, risky behaviors, and clinically significant distress and functional impairment. It is estimated that 70% of the world's population has been exposed to trauma, and although resilience is the norm rather than the exception, approximately 6% of trauma-exposed subjects develop PTSD. The estimated prevalence of PTSD is 20% following interpersonal violence, 25% in combat-exposed veterans, 50% in rape survivors, and as high as 86% in certain refugee populations. PTSD is a recognized risk factor for suicide, increasing the risk of suicide by 6 to 29 times over the general population.
[0265] Available pharmacotherapy options are limited. Selective serotonin reuptake inhibitors (SSRIs) represent the first line of pharmacological treatment; paroxetine and sertraline are the only FDA-approved drugs for the treatment of PTSD. However, despite their established efficacy, these treatments are suboptimal. They are slow-acting antidepressants (SAADs) with a delayed onset of action, with most patients showing significant effects only after at least 4 weeks (and often up to 8 weeks) of continuous treatment. This latency period is clearly troubling because it significantly increases the risk of suicide, self-injury, and other potentially destructive behaviors. Even when delivered optimally, 40% of patients do not respond to SSRIs, and only about 20% to 30% achieve remission, with the magnitude of the difference from placebo ranging from 10% to 20%. In subjects with chronic and complex PTSD, such as veterans, the rates of non-response or partial response to these drugs are comparable to or worse than those in the civilian patient population. In addition, many people classified as "treatment-responders" remain symptomatic and continue to lead restricted lives.
[0266] Trauma-focused psychotherapies have also demonstrated some efficacy in the treatment of PTSD and are often the first-line intervention of choice given the known limitations of pharmacotherapy. Prolonged exposure (PE) and cognitive processing therapy (CPT) are gold standard treatments, but access to appropriately trained therapists is limited, and effective treatment requires a willingness on the part of the patient to expose themselves to trauma-related memories and the distress associated with the experience. Attrition rates in gold standard psychotherapy outcome studies range from 17% to 55.8%, and nonresponse can be as high as 50%. Regardless of treatment modality, disturbing symptoms often persist even in patients classified as treatment responders. Efficacy gaps may also be particularly significant in veterans treated in Veterans Affairs (VA) medical center settings, perhaps at least in part due to the complexity of these patients, who often have significant psychiatric and medical comorbidities and repeated, prolonged trauma exposure. Therefore, there is an urgent need to identify novel, rapidly acting strategies for the treatment of PTSD, delineate the mechanisms underlying treatment action, and, critically, establish baseline markers that predict treatment response.
[0267] Recently, several placebo-controlled clinical trials have demonstrated acute and sustained beneficial clinical effects on PTSD as measured by the clinician-administered PTSD scale for DSM-5 (CAPS-5) following administration of two to three doses of methylenedioxymethamphetamine (MDMA) along with manualized psychotherapy. These robust and sustained clinical effects were recently replicated in a large Phase 3 clinical trial. A second Phase 3 clinical trial is currently ongoing, and favorable clinical results may put MDMA-assisted psychotherapy on track for FDA approval.
[0268] 3,4-Methylenedioxy-N-methylcathinone (methylone; also known as MDMC, βk-MDMA, and M1) is a rapidly acting empathy-enhancing agent (RAE) that is structurally related to MDMA. Recent observational naturalistic studies compared the acute pharmacological and physiological effects of orally administered methylone and MDMA in healthy participants with a history of prior exposure to both compounds. Although these compounds may be mechanistically similar, methylone produces less potent prototypical psychostimulant and empathogenic effects relative to MDMA, including reduced euphoria, intoxication, stimulant-like effects, and changes in cognitive and bodily perceptions, as well as increased sociability. The marked difference in acute pharmacological effects may be explained in part by differences in their serotonin (5-HT) receptor affinities. Methylone has a strong affinity for 5-HT 2A The affinity of 5-HT is significantly lower than that of MDMA. 1A Methylketone also has partial agonist activity on 5-HT compared to MDMA. 2C It has a weak antagonistic effect, while MDMA has partial agonist activity. Methylone also inhibits or reverses the monoamine reuptake transporters of dopamine, norepinephrine, and serotonin, which increases the extracellular concentrations of these neurotransmitters.
[0269] This example presents a more detailed analysis of 21 patients from the previous example (20 patients from the PTSD subset discussed in the previous example, plus one patient from this example who was mischaracterized and subsequently determined to have a primary diagnosis of PTSD) who had a primary diagnosis of PTSD, along with a range of psychiatric comorbidities, and were clinically treated with methylone in an outpatient setting. The patients were not given structured psychotherapy in conjunction with methylone treatment, which is different from recent studies of MDMA that emphasize the importance of a manualized hallucinogen-assisted psychotherapy model. These characteristics, along with methylone's short duration of action and less pronounced acute psychological and physiological effects, make it an attractive agent for clinical use in the treatment of PTSD.
[0270] Materials and Methods
[0271] Archival clinical data were obtained from 21 patients with a primary diagnosis of PTSD who received at least one oral methylone administration as part of dedicated care in an outpatient psychiatric setting. Protected health information was not disclosed and consent for the use of their archival data was not obtained from the patients. Case narratives were systematically compiled from data collected as part of routine clinical work. Diagnosis was confirmed by experienced clinicians using semi-structured interviews. Baseline symptom severity was assessed using the Clinical Global Assessment Scale-Severity (CGI-S). Symptom improvement was assessed using the Clinical Global Assessment Scale-Improvement (CGI-I) after administration. Patients were assessed for any observed or reported safety events after the methylone administration phase of the patient. Because these case narratives were retrospectively examined from routine clinical care records and were not prospectively collected in the study, a more specific validated rating scale for assessing PTSD symptoms was not available. In addition, follow-up was different, with follow-up length ranging from one week (Case 2) to 15 years (Case 16).
[0272] Table 5: Demographic data, clinical characteristics and response to treatment
[0273]
[0274]
[0275] *Case 12: Based on the case description, whether bupropion was a prior or concomitant medication is unknown. Abbreviations: BPD: borderline personality disorder; CBT: cognitive behavioral therapy; F: female; GAD: generalized anxiety disorder; M: male; MDD: major depressive disorder; NR: not reported; PTSD: posttraumatic stress disorder; SCZ: schizophrenia; SSRI: selective serotonin reuptake inhibitor; SNRI: serotonin-norepinephrine reuptake inhibitor; SI: suicidal ideation; UNSP: not specified.
[0276] result
[0277] Methylone produced acute and lasting improvements in both PTSD and depressive symptoms without any significant persistent adverse effects. Clinical data are presented in Table 5. Twelve patients (57%) were female; 19 (90%) were white. The mean age was 47.6 years (range: 25 to 78). Baseline CGI-S scores for all 21 patients ranged between 4 and 7 (i.e., moderate to severe illness; see Figure 4). Six patients (28.6%) were taking SSRI or other psychotropic therapies concomitantly with methylone administration. This is noteworthy because recent MDMA trials in PTSD require patients not to receive other psychotropic drugs because SSRI antidepressants have been shown to attenuate the therapeutic effects of MDMA due to substrate competition. All patients experienced debilitating symptoms regardless of past and / or ongoing psychological and pharmacological treatments. Prior therapies included: SSRI / SNRI (n=14; 66.7%), supportive unstructured therapy (n=8; 38%), structured cognitive and behavioral therapy (n=4; 19%), and unspecified antidepressant therapy (n=3; 14.3%).
[0278] All 21 patients achieved at least minimal improvement (CGI-I 1, 2, or 3) following methylone treatment, with 17 achieving CGI-I 1 (greatly improved, 9 patients) or 2 (very much improved, 8 patients; see Figure 4). This trend was observed even for patients who received only a single dose of methylone (n=9), with 8 patients (89%) achieving a CGI-I score of 1 or 2. For patients with multiple methylone dosing phases (n=12), initial improvement was noted after the initial phase in 83% (n=10) of patients; an additional patient experienced improvement after the second phase.
[0279] Information on the persistence of clinical effect was captured for 17 of the 21 patients. One subject reported no persistent effect (i.e., symptom severity returned to baseline almost immediately), and 16 reported persistent effects (>6 months in 11 patients), with one patient each reporting persistent effects of three months, two months, and one week, respectively. In one of the four case narratives that did not include persistence information, the patient was determined by the treatment group to "no longer qualify as a disorder (i.e., PTSD)" after the fourth methylone dosing period (10 months after the baseline assessment).
[0280] Dosing Overview: Methylone was administered orally. Other medications were not changed during methylone treatment. In many cases, an additional booster dose of methylone was administered 1 hour after the initial dose to extend the therapeutic window and optimize the clinical response. In several cases, treatment was continued, and in some cases, the dose was further escalated in subsequent phases (see Table 5). For 19 patients, booster doses were included in one or more phases. The starting dose was between 100 and 270 mg, and these doses as well as booster doses were selected based on clinical judgment.
[0281] Safety: Methylone was generally well tolerated, and no patient discontinued treatment due to adverse events. A total of four adverse events were noted in three of the 21 patients (two adverse events in one patient); none were considered serious, and none required medical intervention. A 75-year-old male with a history of stable atrial fibrillation (pacemaker) and Parkinson's disease developed dizziness at about the end of his fifth period of use of methylone at a total dose of 300 mg (150 mg, followed by a booster dose of 150 mg, which was the highest dose administered to this patient). This symptom subsided quickly, and the subject felt well at discharge with no other adverse effects. A 70-year-old male took methylone 690 mg (200 mg, followed by a booster dose of 250 mg and 240 mg) during a single dosing period, did not experience any adverse events during that period, but reported insomnia and loss of appetite the night after that period. These symptoms had subsided by the next day. A 78-year-old male reported a flashback-like experience during one treatment period. This patient participated in 5 dosing sessions, with total methylone doses ranging from 100 to 300 mg in each session.
[0282] Patient Reports: A 62-year-old male patient with refractory PTSD (ID=Case 2 in Table 5) who was receiving methylone in combination with ongoing SSRI therapy noted after the first dosing period that "[his] problems seemed to be going away, and in the mind it felt like more was going away than it really was...[and] treatment with methylone was like a new 'window of hope' that made thoughts of suicide seem silly and unnecessary." After a rapid and sustained reduction in PTSD symptoms following the methylone phase alone, he expressed an interest in tapering his SSRI since it was no longer needed. Another patient, a 52-year-old female patient with refractory PTSD and comorbid generalized anxiety disorder (ID=Case 7 in Table 5) described a phase as "the healing of an inner little girl." She expressed the realization that "PTSD would no longer rule [her] life. [She] was there for that inner child, and she communicated with [her], and [they] were healed of [their PTSD]."
[0283] discuss
[0284] In this patient case series with a primary diagnosis of PTSD, high comorbidity rates, and prior treatment attempts, methylone produced rapid symptom improvement as measured by the CGI-I. The majority (90%) had a baseline CGI-S of 5 or greater ("significant" or "severe" illness), with 3 patients in the category of CGI-S 7 (i.e., among the "most severe patients with the disease"). The majority (81%) of patients achieved scores corresponding to "much improved" or "extremely improved" according to the CGI-I ( FIG. 4 ). These effects are similar to those found in a recent controlled clinical trial of MDMA combined with manualized psychotherapy for PTSD, where rapid and robust improvements were observed in severely ill, complex, and refractory patients.
[0285] Methylone was well tolerated with one to ten administrations over a wide dose range (100 to 1,020 mg). Several adverse events were reported in three older patients (70 years and older); these were mild and did not require intervention. No patient discontinued methylone treatment due to adverse events. Notably, none of these adverse events occurred in patients receiving concomitant SSRI therapy.
[0286] Strengths and Limitations: This is the first report of the administration of methylone in patients with PTSD. This case series provides evidence that methylone has utility in the pharmacological treatment of PTSD. However, these data have certain limitations. These participants were treated clinically; the data for this report were collected retrospectively from a review of clinical records. Dosing and follow-up were variable, and there was no randomization, control, or blinding to treatment condition. In addition, the sample lacked diversity and ongoing psychotherapy and medication adjustments during the variable follow-up period may have influenced the clinical course. A strength of this report is the complexity of the sample, which facilitates generalizability. Despite these limitations, these case narratives in a complex patient population constitute the first clinical evidence of the efficacy of methylone in the treatment of PTSD.
[0287] Methylone has not received the same humanistic or clinical attention as MDMA, perhaps due to its milder and shorter-lived psychopharmacological effects (e.g., euphoria, empathogenic effects). However, these "milder" effects may be particularly helpful for some patients who are not well treated with the more intense acute psychological and physiological effects of MDMA.
[0288] Example 6: Methylone in the FST: Effects on Depression, Anxiety, and PTSD
[0289] In this example, it was investigated whether methylone could produce a rapid onset antidepressant-like effect in the rat FST, and the prototype selective serotonin reuptake inhibitor (SSRI) fluoxetine was used as an antidepressant control.
[0290] method
[0291] animal Male Sprague Dawley rats (Charles River Laboratories) weighing 180-200 g upon arrival were used for this study, which was conducted at Melior Discovery (Exton, PA). Rats were acclimated to their home cages for at least one week prior to testing, maintained in a controlled environment with a 12-hour light / dark cycle, with no more than 2 rats per cage. Animals had free access to food and water and were randomly assigned to treatment groups. Animal use and procedures were based on established protocols approved by the IACUC Committee, Melior standard operating procedures (SOPs), and Transcend Therapeutics.
[0292] Forced swim test (FST) : In the FST test, rats were placed in a round plastic glass container filled with water without means of escape. The water temperature was maintained at 22°C to 25°C and varied for each animal. After the adaptation period, the rats were timed for inactivity (failure to struggle), activity, swimming time, and climbing time. Day 1 consisted of a 15-minute adaptation test, and Day 2 (24 hours later) consisted of a 5-minute test. A time sampling procedure was used, in which animals were observed every 5 seconds and scored for immobility, swimming, or climbing. Fluoxetine (10 mg / kg, IP, Sigma Aldrich) or 0.9% sterile saline vehicle (vehicle 3× group) was administered 23.5, 5, and 1 hour before testing in the FST. Methylone (5, 15, or 30 mg / kg, IP; Cayman Chemical) or 0.9% saline vehicle (vehicle 1× group) was administered 30 minutes before the FST test. The experimenter was blind to the treatment.
[0293] Combination research Radioligand binding was performed using standard protocols, using [ 3 H] Citalopram, [ 3 H]WIN35428 and [ 3 [H] Nisoxetine targets serotonin (5HT), dopamine (DA), and norepinephrine (NE) transporters. Radiolabeled 5HT, NE, and DA uptake and release studies were performed in rat brain synaptosomes using standard protocols.
[0294] Statistical analysis : Data for each parameter tested (immobility, swimming or climbing) are presented as mean ± SEM. Differences between groups were determined by one-way analysis of variance and post hoc Tukey's test, where p values less than 0.05 indicated statistically significant differences.
[0295] Results and Conclusions
[0296] A single dose of methylone produced a robust, dose-dependent, and rapid-onset antidepressant-like response in the rat FST ( FIG. 5 ). Of note, 2 to 3 injections of SSRI antidepressants are generally required to elicit behavioral responses in the FST, as indicated by the fluoxetine control group in the current study that received 3 doses of fluoxetine prior to testing ( FIG. 5 ). However, rats treated with a single dose of methylone 30 minutes prior to testing in the FST exhibited a very significant reduction in immobility ( Figure 5A Notably, a single dose of methylone (5, 15, or 30 mg / kg, IP) administered 30 minutes prior to testing reduced immobility by 54%, 99%, or 96%, respectively (p<0.0001), compared to rats receiving saline vehicle. Medium or high doses of methylone significantly increased swimming ( Figure 5B Climbing was increased only at the lowest dose of methylone, reflecting recruitment of noradrenaline-activated receptor activity at this dose level ( Figure 5C ).
[0297] The magnitude of the effect of medium or high doses of methylone was significantly greater (99% and 96% reduction) than that of fluoxetine (56%, Figure 5A ). These data also demonstrate that methylone outperforms other psychedelic drugs. Previous reports of ketamine administration showed a 30% reduction in immobility (Hibicke et al. (2020) ACS Chem. Neurosci 11:864), 25-55% (Yang et al. (2013) Ups J MedSci 118:3), or 60% (Tizabi et al. (2012) Neuroscience 213:72) (reviewed by Weston et al. (2021) Frontiers in Psychiatry 12:659052). LSD and psilocybin have been shown to reduce immobility in the FST by 38% and 67%, respectively (Hibicke, 2020). MDMA (5 or 10 mg / kg) has been reported to reduce immobility in Sprague Dawley rats by 45% and 78%, respectively (Majumder et al. (2011) Behav Pharmacol 22:758-65), but has more robust effects in Flinders Sensitive Line rats (a genetic model of depression) (45% and 93%, respectively, supra). Binding studies have demonstrated methyl ketone binding at 5HT, NE, and DA transporters.
[0298] Overall, in the FST, a typical behavioral assay with well-established specificity and selectivity for antidepressant drugs, methylone produced a more robust antidepressant-like response than the SSRI fluoxetine. The magnitude of the effect of methylone in this test also exceeds that of other hallucinogens and antidepressants tested in the literature in wild-type rats ( Figure 6 ). Although its structure is similar to MDMA, methylone exhibits different effects on monoamine transporter binding, uptake, and release.
[0299] Taken together, these results demonstrate the utility of methylone in treating depression and other CNS disorders where antidepressants are effective, including but not limited to post-traumatic stress disorder (PTSD), mood disorders, anxiety disorders, obsessive compulsive disorder (OCD), and fibromyalgia.
[0300] Example 7: 2C-B in FST: Effects on Depression, Anxiety, and PTSD
[0301] In this example, whether 2C-B can produce a rapid onset antidepressant-like effect in the rat forced swim test (FST) was investigated, and the prototype selective serotonin reuptake inhibitor (SSRI) fluoxetine was used as an antidepressant control.
[0302] method
[0303] animal Male Sprague Dawley rats (Charles River Laboratories) weighing 180-200 g upon arrival were used for this study, which was conducted at Melior Discovery (Exton, PA). Rats were acclimated to their home cages for at least one week prior to testing, maintained in a controlled environment with a 12-hour light / dark cycle, with no more than 2 rats per cage. Animals had free access to food and water and were randomly assigned to treatment groups. Animal use and procedures were based on established protocols approved by the IACUC Committee, Melior standard operating procedures (SOPs), and Transcend Therapeutics.
[0304] Forced swim test: In the FST test, rats were placed in a round plastic glass container filled with water without means of escape. The water temperature was maintained at 22°C to 25°C and varied for each animal. After the adaptation period, the rats were timed for inactivity (failure to struggle), activity, swimming time, and climbing time. Day 1 consisted of a 15-minute adaptation test, and Day 2 (after 24 hours) consisted of a 5-minute test. A time sampling procedure was used, in which animals were observed every 5 seconds and scored for immobility, swimming, or climbing. Fluoxetine (10 mg / kg, IP, Sigma Aldrich) or 0.9% sterile saline vehicle (vehicle 3× group) was administered 23.5, 5, and 1 hour before testing in the FST. 2C-B (2.5, 10, or 20 mg / kg, IP, Cayman Chemical) or 0.9% saline vehicle (vehicle 1× group) was administered 30 minutes before the FST test. The experimenter was blind to the treatment.
[0305] Statistical analysis : Data for each parameter tested (immobility, swimming or climbing) are presented as mean ± SEM. Differences between groups were determined by one-way analysis of variance and post hoc Tukey's test, where p values less than 0.05 indicated statistically significant differences.
[0306] Results and Conclusions
[0307] Single injections of medium or high doses of 2C-B produced rapid onset of antidepressant-like responses in the rat FST, whereas the lowest dose had no effect ( Figure 7 Typically, 2 to 3 injections of SSRI antidepressants are required to elicit behavioral responses in the FST, as demonstrated by the fluoxetine control group in the current study who received 3 doses of fluoxetine prior to testing ( Figure 7 Notably, rats that received a single dose of 2C-B 30 min prior to testing in the FST exhibited a statistically significant reduction in immobility ( Figure 7 A) and accompanied by a significant increase in swimming ( Figure 7 B), consistent with serotonin-activating activity. The magnitude of the effect of the medium and high doses of 2C-B (50% and 53%, respectively) was almost identical to that of the fluoxetine control group (56%). Climbing was significantly reduced only in the group receiving the high dose of 2C-B ( Figure 7 C), but the explanation for this result is unclear.
[0308] Overall, in the FST, a typical behavioral assay with well-established specificity and selectivity for antidepressant drugs, 2C-B produced a faster-onset antidepressant-like response of comparable magnitude to the SSRI fluoxetine. These results demonstrate the utility of 2C-B in treating depression and other CNS disorders in which antidepressants are effective, including but not limited to post-traumatic stress disorder (PTSD), anxiety disorders, obsessive-compulsive disorder (OCD), and fibromyalgia.
[0309] Example 8: Prior SSRI treatment does not interfere with the efficacy of methylone in the rat forced swim test
[0310] Example 6 shows that methyl ketone produces a rapid and robust dose-dependent antidepressant-like effect in the forced swim test (FST), with a magnitude greater than any other antidepressant tested in this model. Selective serotonin reuptake inhibitors (SSRIs) are first-line treatments for a variety of central nervous system (CNS) disorders, including post-traumatic stress disorder (PTSD), major depressive disorder (MDD), anxiety, obsessive-compulsive disorder (OCD), and fibromyalgia. MDMA-assisted psychotherapy is in clinical trials for the treatment of PTSD, where SSRIs are warned to inhibit the efficacy of MDMA-assisted therapy (Feduccia et al. (2021) Psychopharmacology 238:581). If a patient requires MDMA-assisted therapy, they will need to stop receiving their SSRI treatment. Since SSRIs require a gradual reduction in withdrawal periods over multiple weeks, a considerable withdrawal period may be required before a patient can start MDMA treatment. This poses both logistical and safety risks to the most severely affected PTSD subjects. Since SSRIs block the clinical efficacy of MDMA-assisted psychotherapy, in this example, it was investigated whether prior administration of the prototypic SSRI fluoxetine affects behavioral responses to methylone in the FST.
[0311] method
[0312] animal Male Sprague Dawley rats (Charles River Laboratories) weighing 180-200 g upon arrival were used for this study, which was conducted at Melior Discovery (Exton, PA). Rats were acclimated to their home cages for at least one week prior to testing, maintained in a controlled environment with a 12-hour light / dark cycle, with no more than 2 rats per cage. Animals had free access to food and water and were randomly assigned to treatment groups. Animal use and procedures were based on established protocols approved by the IACUC Committee, Melior standard operating procedures (SOPs), and Transcend Therapeutics.
[0313] Drug treatment : Fluoxetine (10 mg / kg, IP, SigmaAldrich) or 0.9% sterile saline vehicle was administered 23.5, 5, and 1 h prior to testing in the FST. Methylone (5 or 15 mg / kg, IP; Cayman Chemical) or 0.9% saline vehicle ( Fig. 8A). Control animals received fluoxetine alone, methylone alone, or saline vehicle. The lower dose of methylone (5 mg / kg) was of interest because it produced a submaximal response in the FST, allowing for the potential detection of changes in immobility that could occur in either direction.
[0314] Forced swim test : In the FST test, rats are placed in a round plastic glass container filled with water without means of escape. The water temperature is maintained at 22°C to 25°C and varies for each animal. After the adaptation period, the rats are timed for inactivity (failure to struggle), activity, swimming time, and climbing time. The experimenter and the scorer are blind to the treatment group. The first day consists of a 15-minute adaptation test, and the second day (24 hours later) consists of a 5-minute test. A time sampling procedure is used, in which animals are observed every 5 seconds and scored for immobility, swimming, or climbing.
[0315] Statistical analysis : Data for each parameter tested (immobility, swimming or climbing) are presented as mean ± SEM. Differences between groups were determined by one-way analysis of variance and post hoc Tukey's test, where p values less than 0.05 indicated statistically significant differences.
[0316] Results and Conclusions
[0317] Three prior doses of fluoxetine had no effect on immobility in response to a single dose of methylone (62% reduction in immobility relative to vehicle; Figure 8B ; F (4,31) =17.05, p<0.0001). Consistent with the results of Example 6, both fluoxetine and methylone (5 mg / kg) reduced immobility by 60% (p<0.001) and 71% (p<0.0001), respectively, compared to vehicle. Notably, combination treatment with a higher dose of methylone (15 mg / kg) reduced immobility by 95% (p<0.0001) compared to vehicle, which is consistent with Example 6.
[0318] Methylketone significantly increased climbing behavior ( Figure 8C ; F (4,31) =5.786, p<0.01) and fluoxetine significantly increased swimming behavior ( Fig.8D ; F (4,31) =6.063, p<0.01), consistent with norepinephrine-activated and serotonin-activated activities, respectively.
[0319] In summary, prior treatment with an SSRI (fluoxetine) was studied and did not affect the behavioral response to methylone in the FST of rats. These findings distinguish methylone from MDMA and suggest that, unlike MDMA, SSRIs do not interfere with the behavioral efficacy of methylone. Since SSRIs are the first line of treatment for many CNS disorders, including PTSD, these findings are particularly encouraging because they suggest that patients can continue to take SSRIs while taking methylone without concern for reduced efficacy.
[0320] Example 9: Effects of methylketone, 2-CB, and MBDB in a mouse model of post-traumatic stress disorder (PTSD)
[0321] Fear extinction memory loss is a characteristic of PTSD in patients (Wicking et al. (2016) Neurobiology of Learning and Memory 136: 116). SSRI antidepressants, similar to the two approved for the treatment of PTSD (i.e., paroxetine and sertraline), prevent fear memory generalization and enhance extinction (Pedraza et al. (2019) Transl Psychiatry 9: 53). The enhancement of fear extinction may also underlie the beneficial effects of MDMA as a treatment for PTSD. (Feduccia and Mithoefer (2018) Progress in Neuro-Psychopharmacology & Biological Psychiatry 84 (Part A), 221-228).
[0322] Effective PTSD treatment promotes dissociation between the traumatic memory and the patient's fear response, so that reminders of the traumatic memory evoke less fear response. This has been modeled in the mouse fear extinction paradigm (see Fig.9A ), which was performed over 3 days. On day 1 (fear conditioning), mice were trained to acquire a "traumatic memory", i.e., a conditioned stimulus (CS, tone) was associated with an unconditioned stimulus (US, foot shock). On day 2 (extinction training), mice were trained to forget the traumatic memory association by presenting the CS 6 times in a novel environment (without the US). On day 3 (extinction recall), mice were "asked" whether the tone (CS) still elicited a fear response, which was measured by the time spent immobilizing when the tone was presented. Less immobilization time means better extinction recall. Drugs that improve extinction recall reduce the immobilization time on day 3, and therefore show potential as a treatment for PTSD.
[0323] Studies with MDMA have shown that after fear conditioning, administration of MDMA (7.5 mg / kg) 30 minutes prior to extinction training enhances extinction recall, measured as a 35% reduction in immobility compared to saline-injected controls (Young et al. (2015) Transl Psychiatry 5:e634).
[0324] Use as Fig.9A The experimental design described in , the results showed that methylone (30 mg / kg) significantly enhanced fear extinction recall by nearly 60% ( Fig. 9B Because effects on motor activity could confound the interpretation of these results, it is noteworthy that there were no differences between the groups in terms of the movements recorded during the duration of the test phase ( Fig. 9C ).
[0325] Use with Fig.9A MBDB was also tested in a fear extinction model of PTSD using an experimental design similar to that outlined in . Mice given a single injection of MBDB (5 mg / kg, IP) demonstrated improved extinction acquisition ( Fig. 10A ), with a small but significant increase in motor activity on day 2 ( Fig. 10B ).
[0326] Example 10: Prior SSRI treatment does not interfere with the efficacy of methylone in the rat forced swim test
[0327] The Open Space Test (OFT) exploits the rodent's innate fear of open spaces to assess anxiety-like behavior. Spending more time in the center of the open space reflects an anxiolytic (anxiolytic) effect.
[0328] A single dose of methylone (5 or 15 mg / kg, IP) administered 30 min before testing significantly increased the time spent in the center of the open field compared to vehicle-treated controls ( Fig.11A ). Locomotor activity was also measured in the OFT. The 5 mg / kg methylone dose had no effect compared to vehicle control, but at 15 or 30 mg / kg methylone doses, locomotor activity was significantly increased ( Fig. 11B ).
[0329] Example 11: Two or three low doses of methylone produced robust antidepressant-like effects comparable to a single high dose in the rat forced swim test.
[0330] This study investigated whether repeated low-dose methylone administrations have antidepressant-like effects in the forced swim test (FST) and how these responses differ from a single higher dose that has maximal effects in the FST. Results reveal whether the robust antidepressant-like responses of methylone are due to C max Still AUC.
[0331] Methods: Male Sprague Dawley rats (Charles River Laboratories) weighing 180-200 g on arrival were used. Rats were acclimated to their home cages for at least one week prior to testing and maintained on a 12-h light / dark cycle in a controlled environment with no more than 2 rats per cage. Rats had free access to standard rodent chow and water and were randomly assigned to treatment groups.
[0332] Methylone hydrochloride (5-15 mg / kg) was formulated in a sterile saline vehicle prior to intraperitoneal administration. Control animals received saline vehicle. The dosing schedule and experimental design schematic can be found in Fig.12 A.
[0333] The FST was performed and scored by an experimenter blinded to the treatment groups according to a standard protocol and according to the "modified FST" procedure (Slattery and Cryan (2012) Nat Protoc, 7: 1009). Briefly, rats were placed in a round plexiglass container (29.2 cm in diameter and 49.5 cm in height) with a water depth of 30 cm so that the rats could not support themselves by touching the bottom of the box. The water temperature was maintained between 22 and 25 °C and was changed for each animal. Day 1 (training) included a 15-minute adaptation trial, and day 2 (test, 24 hours later) included a 5-minute test. Using a time sampling procedure, animals were observed every 5 seconds during the test (60 counts or 5 minutes) and scored for immobility (defined as no struggle), swimming (defined as circular movement around the box), or climbing (defined as upward escape behavior). Data are expressed as the percentage of time spent immobile, swimming, or climbing during the 5-minute test (e.g., immobility counts divided by 60).
[0334] Results: Consistent with the above results, methylone produced a rapid and robust antidepressant-like effect on immobility (F (5,32) =17.67, p<0.0001). (5,32) =17.67, p<0.0001) and swimming (F (5,32) =17.67, p<0.0001). Specifically, single doses of 10 and 15 mg / kg of methylone produced a robust antidepressant-like effect in the FST, significantly reducing immobility time ( Fig.12B). The increase in overall immobility in the 5 mg / kg and 10 mg / kg groups compared to the previous experiment may be due to the current experimental design ( Fig.12 A) Additional stress caused by repeated IP injections.
[0335] Notably, two or three 5 mg / kg doses also significantly reduced immobility. No significant differences were observed between the 2 × 5 and 10 mg / kg groups, or between the 3 × 5 and 15 mg / kg groups, respectively, suggesting that the antidepressant-like effects of methylone are attributable to AUC rather than C max . Using the allometric dose scaling method, a dose of 5 mg / kg in rats correlated to the approximate human dose of 50 mg in humans, a dose at which no side effects were detected in a recent clinical study (Poyatos et al. (2022) Int J Mol Sci, 23:14636). These results confirm the use of lower repeated doses of methylone to produce beneficial effects while potentially reducing side effects.
[0336] Example 12: Methylketones show no agonist / antagonist activity across 168 different GPCRs in a β-arrestin-based screen.
[0337] To identify possible interactions with a selection of known GPCR or orphan GPCR targets, the DiscoverX GPCR Arrestin screen was used to investigate the activity of methyl ketones in 168 GPCRs. Using two concentrations of methyl ketone (1 μmol and 10 μmol), agonist or antagonist activity in the following receptors was determined in an in vitro β-arrestin-based screen.
[0338] Methods: PathHunter cell lines were expanded from frozen stocks following standard procedures. Cells were seeded in a total volume of 20 μL into white-walled 384-well microplates and incubated at 37°C for the appropriate time prior to testing.
[0339] For agonist assays, incubate cells with sample to induce a response. Make an intermediate dilution of sample stocks to generate 5× samples in assay buffer. Add 5 μL of 5× sample to cells and incubate at 37°C or room temperature for 90 to 180 minutes. Vehicle concentration is 1%.
[0340] For antagonist assays, cells were pre-incubated with antagonists and then incubated in EC 80An agonist challenge was performed at 1% concentration. An intermediate dilution of the sample stock was performed to generate a 5× sample in assay buffer. 5 μL of the 5× sample was added to the cells and incubated at 37°C or room temperature for 30 minutes. The vehicle concentration was 1%. 5 μL of 6×EC in assay buffer was added to the cells. 80 agonist and incubate at 37°C or room temperature for 90 or 180 min.
[0341] The detection signal was generated by a single addition of 12.5 or 15 μL (50% v / v) of PathHunter detection reagent cocktail followed by incubation for one hour at room temperature. TM The instrument reads the chemiluminescent signal on the microplate.
[0342] Compound activity was analyzed using the CBIS data analysis suite (ChemInnovation, CA). For agonist mode assays, percent activity was calculated using the following formula: percent activity = 100% x (average RLU of test sample - average RLU of vehicle control) / (average MAX control ligand - average RLU of vehicle control).
[0343] For antagonist and negative allosteric mode assays, percent inhibition was calculated as follows: percent inhibition = 100% x (1 - (average RLU of test sample - average RLU of vehicle control) / (average RLU of EC80 control - average RLU of vehicle control)).
[0344] Compounds that act as agonists activate GPCRs and will result in increased recruitment of beta-arrestin to the target GPCR. To determine if a compound is likely to act as an agonist, activity should be greater than 30%. Compounds that act as antagonists of ligand binding inhibit GPCR activation and will result in decreased recruitment of beta-arrestin to the target GPCR. To determine if a compound is likely to act as an antagonist to inhibit activation, >50% inhibition should be observed.
[0345] Results: At both 1 μM and 10 μM concentrations, methylone failed to meet criteria for agonist or antagonist activity at any of the 168 GPCRs tested. These data suggest that methylone's activity is extremely specific for the monoamine transporters SERT, DAT, and NET and does not appear to interact with known GPCRs or orphan GPCR targets of choice in β-arrestin-based screens.
[0346] Experiment 13: MBDB produces rapid and robust antidepressant-like effects in the forced swim test (FST).
[0347] MBDB is an α-ethyl analog of MDMA. This study tested whether MBDB has antidepressant-like effects in the rat forced swim test (FST). The FST is a classic behavioral test that has been used to screen for antidepressant-like effects for over 40 years. Antidepressants of all classes, including serotonergic antidepressants, tricyclic antidepressants, and even faster-acting antidepressants such as ketamine, have been shown to reduce immobility in the FST, consistent with an antidepressant-like effect. In addition, drugs acting on the serotonergic and noradrenergic systems increase swimming and climbing behaviors in the FST, respectively. Therefore, these behaviors were also measured to gain insight into the mechanisms underlying antidepressant-like behavioral responses.
[0348] Methods: Male Sprague Dawley rats (Charles River Laboratories) weighing 180-200 g on arrival were used. Rats were acclimated to their home cages for at least one week prior to testing and maintained on a 12-h light / dark cycle in a controlled environment with no more than 2 rats per cage. Rats had free access to standard rodent chow and water and were randomly assigned to treatment groups.
[0349] MBDB (15-45 mg / kg) was formulated in a sterile saline vehicle prior to intraperitoneal administration. Control animals received a saline vehicle.
[0350] The FST was performed and scored by an experimenter blinded to the treatment groups according to a standard protocol and according to the "modified FST" procedure. Briefly, rats were placed in a round plexiglass container (29.2 cm in diameter and 49.5 cm in height) with a water depth of 30 cm so that the rats could not support themselves by touching the bottom of the box. The water temperature was maintained between 22 and 25 °C and was changed for each animal. Day 1 (training) included a 15-minute adaptation trial, and day 2 (test, 24 hours later) included a 5-minute test. Using a time sampling procedure, the animals were observed every 5 seconds during the test (60 counts or 5 minutes) and scored for immobility (defined as no struggle), swimming (defined as circular movement around the box) or climbing (defined as upward escape behavior). Data are expressed as the percentage of time spent immobile, swimming or climbing during the 5-minute test (e.g., immobility count divided by 60).
[0351] Results: MBDB significantly reduced immobility (F (3,24) =55.0, p<0.0001)( Fig.13 A). Climbing was significantly reduced only at the highest dose ( Fig.13 B)(F (3,24)=5.649, p<0.01), but swimming was robustly enhanced at all doses tested ( Fig.13 C)(F (3,24) =42.503, p<0.001). These results indicate that MBDB has robust antidepressant-like activity. In addition, since the increase in swimming behavior in the FST is associated with an increase in serotonergic activity, these data also indicate that MBDB exerts its antidepressant-like activity primarily through its effects on the serotonergic system.
[0352] Example 14: Pilot study evaluating the use of methylone to treat PTSD.
[0353] Methylone is a new, potentially effective treatment option for participants with PTSD. The purpose of this pilot study is to evaluate the safety, tolerability, and efficacy of methylone in adult participants with PTSD. The study is conducted in two parts. Part A is open-label and will enroll up to 15 evaluable participants with PTSD. After completion of Part A, enrollment will begin in Part B, which will be double-blind, placebo-controlled, and will enroll up to 64 evaluable participants with PTSD.
[0354] Objectives and Endpoints: This is a two-part study, with safety as the primary objective for Part A and efficacy as the primary objective for Part B. Therefore, each part of this study has different objectives and endpoints, as shown in the table below.
[0355]
[0356]
[0357]
[0358] Abbreviations: 5D-ASC = five-dimensional altered states of consciousness; AE = adverse event; AESI = adverse event of special interest; BDI-II = Beck Depression Inventory-II; DBP = diastolic blood pressure; CAPS-5 = clinician-administered PTSD scale for DSM-5; CGI-I = clinician global impression of improvement; CGI-S = clinician global impression of severity; C-SSRS = Columbia-Suicidality Severity Rating Scale; DBP = diastolic blood pressure; ECG = electrocardiogram; HR = heart rate; MADRS = Montgomery-Åsberg Depression Rating Scale; MEQ-30 = Mystical Experience Questionnaire-30; PCL-5 = PTSD Checklist for Posttraumatic Stress Disorder. DSM-5); PGI-C = Patient Global Impression of Change; PGI-S = Patient Global Impression of Severity; PSQI = Pittsburgh Sleep Quality Index; PTGI = Posttraumatic Growth Inventory; PTSD = posttraumatic stress disorder; SDS = Sheehan Disability Scale; SBP = systolic blood pressure; TEAE = treatment-emergent adverse event; WEMWBS = Warwick-Edinburgh Mental Health Scale.
[0359] Overall Design
[0360] Introduction: This is a two-part study to evaluate methylone for the management of PTSD symptoms. Part A is an open-label, non-controlled evaluation in up to 15 participants with PTSD to assess early safety and efficacy and confirm the procedures included in the blinded portion of this study (Part B). After completion of Part A, recruitment for Part B will begin in up to 64 participants. Part B is identical to Part A, but with the addition of a placebo group.
[0361] The open-label treatment in Part A is:
[0362] · Methylone 150 mg, with a 100 mg booster dose administered 90 (±10) minutes after the first dose in each dose session.
[0363] Part B was a randomized, double-blind, parallel-group, placebo-controlled evaluation of methylone for the management of PTSD symptoms.
[0364] Enrollment includes up to 79 evaluable participants (up to 15 in Part A and up to 64 in Part B); in Part B, up to 40 evaluable participants will be enrolled initially, with an interim analysis to determine if a larger sample size is needed. There are 4 planned dosing periods for each participant. Participants in Part B are randomized 1:1 to one of the two study treatment groups and receive the randomized treatment during each weekly dosing period during the study.
[0365] The two blinded study treatment groups in Part B were:
[0366] · Methylone 150 mg, with a 100 mg booster dose administered 90 (± 10) minutes after the first dose in each dosing period.
[0367] · Matching placebo at each time point (prime + boost) in each dosing period.
[0368] For each participant in Part A and Part B, this study includes:
[0369] · Screening Period (Day -28 to Day -4): Informed consent, eligibility assessment, and recruitment of eligible participants.
[0370] · Baseline / Preparatory Process (Day -3 to Day -1): Baseline assessment leading to recruitment confirmation, eligibility confirmation, and preparatory psychoeducational process.
[0371] · Treatment Period (Day 1 to Day 24): Four dosing sessions per week, and associated remote sessions. Dosing periods last at least 8 hours, or until all effects (physical and psychological) are resolved, whichever is longer. Each dosing period is followed by a safety phone call 1 day after each dose and an efficacy assessment 2 days after each dose. Each dosing session is video recorded for quality assurance and training purposes. Videos are available to ensure mentors follow mentor training.
[0372] · Follow-up period (Day 29 to Day 64): Safety and efficacy follow-up was conducted at 1, 2, 3, and 6 weeks after the final study dose. In addition, there was a mentor-led reflection process at 1, 2, and 3 weeks after the final study dose. Participants were contacted by telephone for follow-up on Day 57 (±2 days).
[0373] · Discontinuation: Participants who discontinued early were invited to return for an additional visit to repeat the 6-week end-of-study (EOS) visit.
[0374] The expected participation duration for each participant who completes all study visits from Screening to EOS visit is up to 16 weeks.
[0375] Study participants
[0376] Medically healthy adult participants, aged 18 to 65 years (inclusive), had to meet the diagnostic criteria for current moderate to severe PTSD in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM5), with symptom duration of at least 6 months at screening, as assessed by the Mini-International Neuropsychiatric Interview (MINI) 7.0.2, CAPS-5, and DSM-5 Life Event Checklist (LEC-5), and had to have failed at least one PTSD treatment (psychotherapy or pharmacotherapy).
[0377] In addition, participants must not have a primary diagnosis of any other DSM-5 disorder as assessed by the MINI version 7.0.2, or any medical history, physical or psychological symptoms, medications, or other relevant findings that, based on the investigator's clinical judgment, would make the participant unsuitable for participation in this study.
[0378] Duration of treatment:
[0379] The duration of treatment was the same for both Parts A and B: four weeks, with weekly dosing (Day 1, Day 8 [±1 day], Day 15 [±1 day], and Day 22 [±1 day]).
[0380] Data monitoring:
[0381] The goals of the Data and Safety Monitoring Board (DSMB) were to review the safety data (Part A and Part B), review the interim analysis reports, and make recommendations on the advisability of increasing the sample size for Part B.
[0382] The DSMB meeting was planned to be held after the eight participants in Part A completed the Day 29 follow-up, after the EOS if a participant withdrew early (safety run-in phase), and once at the end of Part A enrollment.
[0383] For Part B, DSMB meetings were held at intervals of approximately 20 participants (10 in each treatment group). At least two DSMB meetings were scheduled. The first DSMB meeting was held after 20 participants completed the Day 29 follow-up visit or after the EOS in the event of early withdrawal and included an interim efficacy report to determine if the sample size was appropriate. If more than 40 participants were expected to be enrolled, a second DSMB meeting was held after at least 40 participants had had the opportunity to complete the study. Special DSMB meetings could be held as needed.
[0384] The interim analysis focused on the CAPS-5 data and was used only for sample size assessment. There were no stopping rules for efficacy or futility.
[0385] Dosage and route of administration:
[0386] During each dosing period, participants fasted for 2 hours before dosing until 2 hours after the first dose. Methylone (or matching placebo in Part B) was administered orally on Days 1, 8 (±1 day), 15 (±1 day), and 22 (±1 day). A first dose of 150 mg of methylone (or matching placebo in Part B) was given, followed by a booster dose of 100 mg of methylone (or matching placebo in Part B) 90 (±10) minutes later.
[0387] Evaluation criteria:
[0388] Safety was assessed by adverse event (AE) reporting, AESI monitoring, 12-lead-ECG, vital signs, physical examination, and clinical laboratory evaluations; suicidal ideation and behavior were assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS).
[0389] Efficacy was assessed using several psychometric assessments and scales evaluating PTSD symptoms and quality of life.
[0390] Additionally, sleep quality, treatment satisfaction, and psychedelic effects were assessed.
[0391] Statistical analysis:
[0392] Safety parameters for Parts A and B are presented and summarized using descriptive statistics.
[0393] All efficacy endpoint data are presented for individual participants. All continuous efficacy endpoint data are also summarized by study part, overall, treatment (Part B), and study period using descriptive statistics (n, arithmetic mean, standard deviation [SD], median, minimum, and maximum). All categorical efficacy endpoints are summarized using descriptive statistics (n, percentages).
[0394] For Part A, the change from baseline to each time point is presented together with the p value from paired t-test.
[0395] A mixed model for repeated measures was fitted to select efficacy endpoints to analyse differences between treatments in Part B. The model included treatment as a fixed effect, whereas visit and treatment by visit were mixed effects. Baseline values were included as covariates (where applicable), and participant as a random effect. An alpha of 0.1 was used for this analysis.
[0396] Example 15: Methylketone binds differently to the serotonin transporter (SERT) than MDMA.
[0397] MDMA binds to the serotonin transporter (SERT) at the central site (i.e., the site where serotonin binds to serotonergic antidepressants) and at allosteric sites (Islas et al. (2021) Heliyone 07784; Islas and Scior (2022) Molecules 27:2977). It is speculated that the allosteric binding of MDMA to SERT is the reason for its supraphysiological effects to increase presynaptic serotonin release and depletion and interfere with SSRI antidepressants, which has been described in patients and animal models (Feduccia et al. (2021) Psychopharmacology 238:581; Callaway et al. (1990) J Pharmacol Exp Ther, 254:456; Geyer (1994) Neuropsychopharmacology 10:768S).
[0398] To test whether the action of methyl ketone on SERT is orthosteric or allosteric, a series of concentrations of [ 3 H]5HT uptake of serotonin (5HT). If high concentrations of [ 3 H]5HT exceeds the effect of methyl ketone, indicating competitive (i.e., orthosteric) inhibition. In other words, methyl ketone causes K d Shift right (i.e. increase its value), but make B max In the presence of two concentrations of methyl ketone, [ 3 Three thermal saturation curves were run for H]5HT.
[0399] Fig.14 The results shown in indicate that the interaction with methyl ketones on SERT is competitive, as K d Furthermore, as 5HT concentrations increase, the inhibitory effect of methylketone is overcome, so that B max No decline.
[0400] The fact that methylone apparently binds only to the central site of SERT and not allosterically like MDMA could mechanistically explain why methylone does not deplete serotonin like MDMA (Baumann et al. (2012) Neuropsychopharmacology 37:1192) and suggest an improved safety profile. These results could also explain why SSRI antidepressants interfere with the effects of MDMA (Feduccia et al. (2021) Psychopharmacology 238:581) but not methylone (Warner-Schmidt et al. (2023 Jan 10) Frontiers in Psychiatry).
[0401] Example 16: Unlike MDMA, methylone does not bind to the 5HT2B receptor, which is a positive distinction for methylone in terms of cardiovascular safety.
[0402] Agonists of the serotonin 5HT2B receptor are closely related to drug-induced valvular heart disease. In fact, in drug development, 5HT2B excitement is considered a toxic signal (Cavero et al. (2014). Journal of Pharmacological and Toxicological Methods 69:150). MDMA has been shown to be a non-selective agonist of the 5HT2B receptor (Setola et al. (2003) Molecular Pharmacology 63:1223). In this example, methyl ketone was tested to determine whether it showed any affinity for the 5HT2B receptor by competitive radioligand binding.
[0403] Methods: Human serotonin 5HT2B receptor membrane preparations were used to screen racemic methyl ketone hydrochloride and reference compound SB204741. Compounds were dissolved in DMSO (10 mM) and stored frozen at -20°C. On the day of the assay, compounds were thawed and diluted to 5 times the final maximum assay concentration with assay buffer (e.g., if the final assay concentration is 10 μM, dilute to 50 μM). Human serotonin 5HT2B receptor membrane preparations were divided into equal parts. On the day of the assay, membranes were diluted 1:200 in incubation buffer. The assay was performed in a 96-well plate with a final volume of 250 μL per well. 150 μL of membrane preparation, 50 μL of test compound, nonspecific compound, or buffer alone, and 50 μL of radioligand were added to each well. Incubate at 35°C for 90 minutes with gentle stirring. After incubation, use a 96-well FilterMate TMThe filter was then dried in a stream of warm air, sealed with polyethylene, and scintillation cocktail was added. Radioactivity was counted in a TriLux 1450 MicroBeta counter. For each concentration of drug, nonspecific binding was subtracted from total binding to give specific binding. The data were fitted using a nonlinear curve fitting routine from Graphpad Software Inc. to determine the IC 50 K was then calculated using the Cheng Prusoff equation i .
[0404] Results: Fig.15 As shown, methyl ketone has no affinity for 5HT2B receptors, IC 50 =4285nM, K i =3749nM. In contrast, the K i The values are 500nM and 100nM, respectively, and the affinity for 5HT2B receptor is 7.5-37 times that of methyl ketone.
[0405] In summary, these data strongly suggest that methylone provides improved cardiovascular safety compared to MDMA. It will be appreciated by those skilled in the art that changes may be made to the above-described embodiments without departing from the broad inventive concepts of the present invention. Therefore, it is to be understood that the present invention is not limited to the particular embodiments disclosed, but is intended to encompass modifications within the spirit and scope of the invention as defined in the appended claims.
Claims
1. A method for treating and / or preventing a neuropsychiatric disorder and / or ameliorating symptoms thereof in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of methyl ketone (3,4-methylenedioxy-N-methylcathinone).
2. The method of claim 1, wherein the neuropsychiatric disease is depression.
3. The method of claim 2, wherein the depression is selected from the group consisting of: intrusive mood dysregulation disorder; major depressive disorder; single episodes and recurring; persistent depressive disorder (dysthymia); premenstrual dysphoric disorder; substance / medication-induced depression; depression due to another medical condition; other specified depression; unspecified depression; and combinations thereof.
4. The method of claim 1, wherein the neuropsychiatric disorder is post-traumatic stress disorder (PTSD).
5. The method of claim 1, wherein the neuropsychiatric disorder is acute stress disorder.
6. The method of claim 1, wherein the neuropsychiatric disease is personality disorder (PD).
7. The method of claim 6, wherein the personality disorder is selected from the group consisting of: borderline personality disorder (BPD), avoidant personality disorder (AvPD), antisocial personality disorder (AsPD), schizotypal personality disorder, other anxiety and panic producing disorders, specific personality disorders, impulse disorders, gender identity disorders, paraphilias, other sexual disorders, other adult personality and behavioral disorders, unspecified adult personality and behavioral disorders, personality and behavioral disorders attributed to a known physiological condition.
8. The method of claim 6, wherein the subject suffers from depression.
9. The method of claim 1, wherein the neuropsychiatric disorder is an anxiety disorder.
10. The method of claim 9, wherein the anxiety disorder is selected from the group consisting of: generalized anxiety disorder; panic disorder; panic attacks; phobic anxiety disorders; illness anxiety disorders; dissociative, stress-related, somatoform other non-psychotic psychiatric disorders; acute stress response; transient adaptation response; neurasthenia; psychophysiological abnormalities; obsessive-compulsive disorder; response to severe stress and adjustment disorders; separation anxiety disorder; intermittent paroxysmal anxiety; selective mutism; specific phobias; social anxiety disorder (social phobia); agoraphobia; substance / drug-induced anxiety disorders; anxiety disorders attributed to another medical condition; pregnancy and childbirth anxiety; antenatal (pre-delivery) pregnancy anxiety; postpartum anxiety; zoophobia; spider phobia; other animal phobias; natural environmental phobias; thunderstorm phobia; blood phobia; injection and infusion phobia; other medical care phobias; fear of injury; situational phobias; claustrophobia; acrophobia; other unspecified anxiety disorders; body dysmorphia; hoarding disorder; trichotillomania (hair pulling disorder); skin picking (skin picking disorder); and combinations thereof.
11. The method of claim 1, wherein the neuropsychiatric disease is a mood disorder.
12. The method of claim 1, wherein the neuropsychiatric disorder is fibromyalgia.
13. The method of claim 1, wherein the neuropsychiatric disorder is an eating disorder.
14. The method according to any one of claims 1-13, wherein methyl ketone is administered in a dose of 5 mg to 250 mg.
15. The method of any one of claims 1-13, wherein methylketone is administered at a dose of 0.08 mg / kg to 4 mg / kg.
16. The method of any one of claims 1-13, wherein the methylketone is administered more than once per week.
17. The method of claim 16, wherein the methylone is administered once a week, twice a week, three times a week, four times a week, five times a week, or six times a week.
18. The method of any one of claims 1-13, wherein the neuropsychiatric disease is refractory.
19. The method of any one of claims 1-13, wherein the subject is suicidal.
20. The method of any one of claims 1-13, wherein the methylketone is used in combination with an additional therapy for a neuropsychiatric disorder.
21. The method of claim 20, wherein the additional therapy is psychotherapy.
22. The method of claim 20, wherein the additional therapy comprises administering one or more additional psychoactive agents to the subject.
23. The method of claim 22, wherein the additional psychoactive agent is selected from the group consisting of a selective serotonin reuptake inhibitor (SSRI), a tricyclic antidepressant (TCA), a monoamine oxidase inhibitor (MAOI), a serotonin-norepinephrine reuptake inhibitor (SNRI), a serotonin-norepinephrine-dopamine reuptake inhibitor (SDNRI), and an anxiolytic.
24. The method of claim 23, wherein the additional psychoactive agent is a selective serotonin reuptake inhibitor (SSRI).
25. The method of claim 24, wherein the subject is taking the SSRI concurrently or in conjunction with the methylone.
26. The method of any one of claims 1-13, wherein the administering step comprises administering an initial dose of methylone which is then boosted 30 minutes to 4 hours later by administering a second dose of methylone in an amount of about 10% to 100% of the initial dose.
27. A method for treating and / or preventing a neuropsychiatric disease and / or ameliorating symptoms thereof in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of 2C-B (4-bromo-2,5-dimethoxyphenethylamine).
28. The method of claim 27, wherein the neuropsychiatric disorder is depression.
29. The method of claim 28, wherein the depression is selected from the group consisting of: intrusive mood dysregulation disorder; major depressive disorder, single episode and recurrent; persistent depressive disorder (dysthymia); premenstrual dysphoric disorder; substance / medication-induced depression; depression attributed to another medical condition; other specified depression; unspecified depression; and combinations thereof.
30. The method of claim 27, wherein the neuropsychiatric disorder is post-traumatic stress disorder (PTSD).
31. The method of claim 27, wherein the neuropsychiatric disorder is somatic symptom disorder.
32. The method of claim 31, wherein the somatic symptom disorder is selected from the group consisting of illness anxiety disorder, conversion disorder (functional neurological symptom disorder), psychological factors affecting other medical conditions, factitious disorders, other specified physical symptoms and related disorders, unspecified physical symptoms and related disorders, and combinations thereof.
33. The method of claim 27, wherein the neuropsychiatric disorder is fibromyalgia.
34. The method of any one of claims 27-33, wherein 2C-B is administered at a dose of 5 mg to 250 mg.
35. The method of any one of claims 27-33, wherein 2C-B is administered at a dose of 0.08 mg / kg to 4 mg / kg.
36. The method of any one of claims 27-33, wherein the 2C-B is administered more than once per week.
37. The method of claim 36, wherein the 2C-B is administered once a week, twice a week, three times a week, four times a week, five times a week, or six times a week.
38. The method of any one of claims 27-33, wherein the neuropsychiatric disease is refractory.
39. The method of any one of claims 27-33, wherein the subject is suicidal.
40. The method of any one of claims 27-33, wherein the 2C-B is used in combination with an additional therapy for a neuropsychiatric disorder.
41. The method of claim 40, wherein the additional therapy is psychotherapy.
42. The method of claim 40, wherein the additional therapy comprises administering one or more additional psychoactive agents to the subject.
43. The method of claim 42, wherein the additional psychoactive agent is selected from the group consisting of a selective serotonin reuptake inhibitor (SSRI), a tricyclic antidepressant (TCA), a monoamine oxidase inhibitor (MAOI), a serotonin-norepinephrine reuptake inhibitor (SNRI), a serotonin-norepinephrine-dopamine reuptake inhibitor (SDNRI), and an anxiolytic.
44. The method of claim 43, wherein the additional psychoactive agent is a selective serotonin reuptake inhibitor (SSRI).
45. The method of claim 44, wherein the subject is taking the SSRI concurrently or in conjunction with the 2C-B.
46. The method of any one of claims 27-33, wherein the administering step comprises administering an initial dose of 2C-B, which is then boosted 30 minutes to 4 hours later by administering a second dose of 2C-B in an amount of about 10% to 100% of the initial dose.
47. A method for treating and / or preventing a neuropsychiatric disease and / or ameliorating symptoms thereof in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of MBDB (N-methyl-1-(1,3-benzodioxol-5-yl)-2-aminobutane).
48. The method of claim 47, wherein the neuropsychiatric disorder is depression.
49. The method of claim 48, wherein the depression is selected from the group consisting of: intrusive mood dysregulation disorder; major depressive disorder; single episodes and recurring; persistent depressive disorder (dysthymia); premenstrual dysphoric disorder; substance / medication-induced depression; depression attributed to another medical condition; other specified depression; unspecified depression; and combinations thereof.
50. The method of claim 47, wherein the neuropsychiatric disorder is post-traumatic stress disorder (PTSD).
51. The method of claim 47, wherein the neuropsychiatric disorder is anxiety disorder.
52. The method of claim 51, wherein the anxiety disorder is selected from the group consisting of: generalized anxiety disorder; panic disorder; panic attacks; phobic anxiety disorders; illness anxiety disorders; dissociative, stress-related, somatoform other non-psychotic psychiatric disorders; acute stress response; transient adaptation response; neurasthenia; psychophysiological abnormalities; obsessive-compulsive disorder; response to severe stress and adjustment disorders; separation anxiety disorder; intermittent paroxysmal anxiety; selective mutism; specific phobias; social anxiety disorder (social phobia); agoraphobia; substance / drug-induced anxiety disorders; anxiety disorders attributed to another medical condition; pregnancy and childbirth anxiety; antenatal (pre-delivery) pregnancy anxiety; postpartum anxiety; zoophobia; spider phobia; other animal phobias; natural environmental phobias; thunderstorm phobia; blood phobia; injection and infusion phobia; other medical care phobias; fear of injury; situational phobias; claustrophobia; acrophobia; other unspecified anxiety disorders; body dysmorphia; hoarding disorder; trichotillomania (hair pulling disorder); skin picking (skin picking disorder); and combinations thereof.
53. The method of any one of claims 47-52, wherein MBDB is administered at a dose of 5 mg to 250 mg.
54. The method of any one of claims 47-52, wherein MBDB is administered at a dose of 0.08 mg / kg to 4 mg / kg.
55. The method of any one of claims 47-52, wherein the MBDB is administered more than once per week.
56. The method of claim 55, wherein the MBDB is administered once a week, twice a week, three times a week, four times a week, five times a week, or six times a week.
57. The method of any one of claims 47-52, wherein the neuropsychiatric disease is refractory.
58. The method of any one of claims 47-52, wherein the subject is suicidal.
59. The method of any one of claims 47-52, wherein the MBDB is used in combination with an additional therapy for the neuropsychiatric disease.
60. The method of claim 59, wherein the additional therapy is psychotherapy.
61. The method of claim 59, wherein the additional therapy comprises administering one or more additional psychoactive agents to the subject.
62. The method of claim 61, wherein the additional psychoactive agent is selected from the group consisting of an SSRI, a TCA, a MAOI, a SNRI, a SDNRI, and an anxiolytic.
63. The method of claim 62, wherein the additional psychoactive agent is a selective serotonin reuptake inhibitor (SSRI).
64. The method of claim 63, wherein the subject is taking the SSRI concurrently or in conjunction with the MBDB.
65. The method of any one of claims 47-52, wherein the administering step comprises administering an initial dose of MBDB which is then boosted 30 minutes to 4 hours later by administering a second dose of methylone in an amount of about 10% to 100% of the initial dose.
